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2 Thesis Abstract 
Background: Understanding and treating tendon injury is of paramount importance in horses and 
humans. As an alternative to animal models, basic research questions related to tendon injury and 
healing may possibly be better answered with in vitro models utilizing tendon-derived fibroblasts, 
termed tenocytes. Unfortunately, tenocytes display an unstable phenotype in vitro and tend to 
dedifferentiate when expanded under normal 2-D culture conditions, thereby limiting their usage in 
tissue engineering and regenerative medicine.  By contrast, tenocytes cultured in 3-D systems with 
different growth factors and mechanical stimuli, have been shown to maintain a more tenogenic-like 
phenotype. One such 3-D system is the hanging drop culture. This system has the capacity to 
generate self-assembled 3-D spheroidal microtissues (MTs), which may serve to act as building blocks 
for tissue engineering applications. 
Objectives: The primary objectives of this Thesis were to characterize equine adult tenocytes (EATs), 
equine fetal tenocytes (EFTs) and equine multipotent stromal cells (MSCs) in the MT format and to 
evaluate different techniques by which to maintain their differentiation status. 
Materials and Methods: MTs consisting of equine tenocytes, MSCs or co-cultures thereof were 
generated using hanging drop technology and cultured with defined growth media supplements. The 
tenogenic status of these cells in MTs and respective monolayer cultures were evaluated using 
histological techniques and through the use of genetic- and protein-based assays.  
Results and Conclusions: We could demonstrate that equine tenocytes, MSCs and co-culture thereof 
formed spheroidal MTs. In contrast to EFTs, which showed increased rates of apoptosis, EATs 
retained a more differentiated state when cultured as MTs, especially in low serum-containing 
medium supplemented with TGF-β1, insulin and L-ascorbic acid 2-phosphate, as made evident by 
increased expression levels of pro-tenogenic markers and tenocyte-like appearance when 
incorporated into collagen scaffolds. However, the culturing of equine MSCs with tenocytes had no 
stimulatory influence on MSC tenogenesis or on tenocytes. Taken together, our findings demonstrate 
the beneficial effects of culturing tenocytes as gravity-enforced microtissue spheroids and supports 
the use of low-serum containing growth medium in combination with TGF-β1, insulin and ascorbic 
acid as an effective means by which to maintain the tenogenic differentiation status of cultured 
tenocytes. This therefore raises the interesting possibility of whether such a system could be directly 
incorporated into future in vivo tissue engineering strategies for the purpose of more effectively 
treating tendon disorders.  Further studies are needed, also to evaluate a possible influence of 
mechanical stimulation on tenogenic differentiation and for the use of MTs as building blocks for 
tissue engineering approaches.  
Abbreviations 
 
 
 
 
8 
3 Abbreviations 
ACAN   aggrecan 
ADAMTS  a disintegrin and metalloproteinase with thrombospondin motifs 
ALSDFT   accessory ligament of the SDFT  
ASCs    adipose-derived stromal cells 
ASC-MT  MT composed of ASCs 
bFGF   basic fibroblast growth factor 
BAPN   beta-aminopropionnitrile fumarate 
BMA   bone marrow aspirate 
BMP   bone morphogenetic protein 
BMSCs   bone marrow-derived stromal cells 
CABMM  Center for Applied Biotechnology and Molecular Medicine 
CAF    cell-activating factor 
COL1   type I collagen 
COMP    cartilage oligomeric matrix protein  
COX   cyclooxygenase 
CTGF    connective tissue growth factor 
DDFT   deep digital flexor tendon 
DCN   decorin 
DMSO    dimethyl sulfoxide 
EATs   equine adult tenocytes 
ECM   extracellular matrix 
EFTs   equine fetal tenocytes 
EGF   epidermal growth factor  
ESCs   embryonic stem cells 
FACITs   fibril-associated collagens with interrupted triple helices 
GAG   glycosaminoglycan 
GDF   growth and differentiation factor 
GFP   green fluorescence protein 
GM   growth medium 
HA   hyaluronic acid 
HGF   hepatocyte growth factor 
IGF-1   insulin-like growth factor-1 
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IL-1β    interleukin-1β 
IL-1Ra   interleukin-1β receptor antagonist 
iPSCs   induced pluripotent stem cells 
MTs   microtissues 
PDGF   platelet-derived growth factor 
PGE2    prostaglandin E2 
PLGA    polylactic-coglycolic acid 
PRP   platelet rich plasma 
PSGAGs  polysulfated glycosaminoglycans 
ML   monolayer 
MMP   matrix metalloproteinase 
MSCs   multipotent stromal cells 
NGF   nerve growth factor 
SCX   scleraxis 
SDFT   superficial digital flexor tendon 
SL   suspensory ligament  
SLRPs    small leucine-rich proteoglycans  
TIMP   tissue inhibitor of metalloproteinase 
TNC   tenascin-C 
TGF-β   transforming growth factor beta 
TNMD   tenomodulin 
THBS4   thrombospondin-4 
UTC    ultrasonographic tissue characterization 
VEGF   vascular endothelial growth factor 
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4 Introduction 
Tendon injury is one of the most common forms of musculoskeletal injuries that occur to horses 
competing in all disciplines. Injuries to the musculoskeletal system have been found to account for 
82% of all injuries to racehorses competing in National Hunt and flat racing and of theses 46% 
involved tendons or ligaments (1, 2). A study by Pinchbeck et al. reported that tendon or ligament 
strain accounts for 53% of musculoskeletal injuries that occur during hurdle and steeplechase races 
(3). An epidemiological study over a period of 12 years identified tendon injury as the most common 
cause for retirement in racing Thoroughbreds in Hong Kong (4). Over a period of one season, 15% of 
the National Hunt horses (4) and Thoroughbred flat racehorses (5) in training suffered from a tendon 
or ligament injury. The majority of tendon injuries in racehorses appear in the forelimb (97-99%) (4, 
5) with the superficial digital flexor tendon (SDFT) being injured in 75-93% of cases and the remaining 
injuries occurring to the suspensory ligament (SL) (2, 5). But it is not only in the Thoroughbred race 
horse population where tendon injuries represent an important economic and well fare issue. 
Tendon injuries appear in any type of equestrian sport as well as in pleasure horses. Depending on 
the discipline and thereby the demands on the locomotory system, the incidence of fore- and hind 
limb involvement as well as the affected tendinous structure varies, with the energy storing tendons 
(i.e. the SDFT and the SL) being most commonly affected (6-11). The significance of tendon injury is 
not limited to horses but is also of paramount importance in human medicine. Tendon injuries are 
reported to represent 30% of the musculoskeletal caseload in a one year study of human general 
practitioners (12) and tendinopathy is reported to be the cause of 30-50% of all sports-related 
injuries (13). In humans, tendinopathy is most commonly diagnosed in the Achilles, patellar, rotator 
cuff and medial/lateral elbow tendons (14-16). Equivalent to the different sporting disciplines in 
horses, different sporting activities in humans places different tendons at risk. The prevalence of 
elbow tendinopathy in tennis players can be as high as 40% (17). Due to an increase in the aged 
population and a rise in participation in recreational and competitive sporting activities, the 
incidence of tendon injury in humans has risen in recent decades (18, 19). Tendinopathy is a widely 
accepted generic term that encompasses any abnormal condition of a tendon (20). Still more 
common in veterinary medicine are the terms tendonitis and tendinosis, also taking preexisting 
degenerative changes into account. 
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4.1 Functions of tendon 
Tendon and ligaments are connective tissue that guide motion, share loads, and transmit forces in a 
manner that is unique to each tissue, as well as the anatomical site and biomechanical stresses to 
which they are subjected (21). Tendons possess different properties depending on function. As in 
humans, tendons in the horse can be subdivided into two broad categories, the positional tendons 
and the weight bearing tendons.  The positional tendons flex, extend or rotate joints. Weight bearing 
tendons, such as the equine flexor tendons, located on the palmar/plantar aspect of the equine distal 
limb (Fig. 1) receive large weight bearing loads because of the hyperextended metacarpophalangeal 
in the front limb and metatarsophalangeal joint in the hind limb. Weight bearing tendons are more 
elastic than positional tendons and therefore function as elastic energy stores (22). With the spring-
like design of the equine distal limbs, they store energy from weight-bearing for the subsequent 
stride (23). From the tendons and ligaments positioned on the palmar/plantar aspect of the equine 
distal limb, this is essentially true for the SDFT and the SL which act as the main energy storing 
tendons and therefore allow for energy efficient locomotion (24). Additional functions of the flexor 
tendons and ligaments positioned on the palmar/plantar aspect of the distal limb (termed as the 
suspensory apparatus) are to support the hyperextended metacarpophalangeal and 
metatarsophalangeal joint. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Anatomy of the equine distal limb:  
superficial digital flexor tendon (SDFT), deep digital flexor tendon (DDFT), 
suspensory ligament (SL), accessory ligament of the deep digital flexor 
(AL-DDF) (23) 
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4.2 Tendon anatomy and composition 
Tendon is a fibrous connective tissue that is composed of cells within an extracellular matrix rich in 
collagens, proteoglycans, and water (25). The biomechanical characteristics of tendon are 
determined by the composition and organization of the extracellular matrix. Tenocytes, which 
constitute 90- to 95% of the cellular elements of tendons, are essential for the formation and 
maintenance of the extracellular matrix. At least three different populations of tenocytes, based 
mainly on their nuclear morphology on light microscopy, have been identified in equine tendon and 
ligament (26, 27). Type I cells with thin, spindle-shaped nuclei, type II cells with more rounded, thick, 
cigar-shaped nuclei and type III cells, with cartilage-like appearance with round nuclei and visible 
nucleoli. The proportion of these cells varies between tendon and ligaments, along with tendon site 
and age. Less mature tendon has considerably larger numbers of type II cells, whereas type I cells 
predominate with aging. Type III cells are identified in areas subjected to compressive forces 
(fibrocartilagenous zone). Although the activity of the different cell types is unknown, it is possible 
that they are involved in mediating different states of extracellular matrix production (22). Tenocytes 
exhibit long cytoplasmic processes, which link together other tenocytes via gap junctions and thereby 
allow for communication between cells and appropriate responsiveness to mechanical stimuli (28). 
The remaining 5- to 10% of the cellular elements of tendons consist of chondrocytes at the bone 
attachment and insertion sites, synovial cells of the tendon sheaths, and vascular cells, including 
capillary endothelial cells and smooth muscle cells of arterioles. 
The tendon extracellular matrix is composed predominantly of water (about 65% of wet weight), 
collagen (about 30% of wet weight) and non-collagenous glycoproteins (about 5% of wet weight). 
Collagens and proteoglycans account for 70-80% of the dry weight, including small leucine-rich 
proteoglycans (29). The fibril forming type I collagen represents about 95% of the total collagen. The 
remaining 5% are made up mainly of type III and V collagens. In contrast to the mid-substance of the 
tendon, type II and III collagen are predominant in the fibrocartilaginous zone, where only minor 
amounts of type I, IX and X collagen are present (21).  
The hierarchical structure of tendon and its functional properties are determined by the collagen 
types present, as well as their supramolecular organization (Fig. 2). The fibril is the smallest tendon 
structural unit consisting of collagen molecules. Bundles of fibrils are organized as fibers, which are 
grouped together with tenocytes as fascicles. Fascicles are surrounded by a cellular, loose connective 
tissue, the endotenon. In relaxed tendon, the fascicles have a waveform known as crimp, which is 
partly responsible for tendon elasticity. The endotenon carries blood vessels and nerves and contains 
a different type of cell. These more rounded cells are believed to represent a source of multipotent 
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stromal cells (MSCs) within the tendon (30). Bundles of fascicles are enclosed by the epitenon. More 
superficially, a third layer of connective tissue called the paratenon surrounds the tendon. Epitenon 
and paratenon, both reducing friction with the adjacent tissues, are termed peritendon (31).  
 
 
 
 
 
 
 
Figure 2: The organizational structure of tendon (32) 
 
Two classes of regulatory molecules are involved in the regulation of linear and lateral fibril growth, 
the small leucine-rich proteoglycans (SLRPs) and the fibril-associated collagens with interrupted triple 
helices (FACITs). From the SLRPs, two sub-classes exist. In tendon, decorin (class 1) and fibromodulin 
(class 2) are dominant in this regulation, but can be modulated by biglycan (class 1) and lumican 
(class 2). The FACITs closely interact with the fibril forming collagens and affect surface properties as 
well as fibril packing (21). The FACITs XII and XIV have been identified during tendon development 
(33, 34). Cartilage oligomeric matrix protein (COMP) is also thought to be involved in in the 
organization of the collagen fibril framework during normal growth and development. Experimental 
data have shown that COMP accelerated collagen fibril formation in vitro and that levels of COMP 
increase dramatically during growth and peak at around 2 years of age in the tensional region of the 
equine digital flexor tendons (35). The importance and relevance of this protein is further suggested 
by a correlation between ultimate tensile strength of the tendon and the level of COMP at skeletal 
maturity (36). However, knockout studies in COMP-null mice have not found any tendon 
abnormalities (37). The collagen fibrils themselves, as well as the covalent intra- and interfibril 
collagen cross links and electrostatic cross links provided by non-collagenous proteins, contribute to 
the tendon´s biomechanical properties (22). Furthermore elastic fibers are a prerequisite for the 
elastic modulus of tendon (38).  
 
 
Introduction 
 
 
 
 
14 
4.3 Epidemiology of tendon injury 
Overstrain tendon injuries have been shown to significantly impact on the athletic performance and 
significantly increase morbidity and mortality rates in racehorses (1, 2, 5) as well as in horses 
performing in other sporting disciplines (6-10). Several studies in racehorses are available, which 
identify the SDFT and second the SL to be the most prevalent injured structure (2, 5) with the 
forelimbs being 4-5 times more likely to be affected (1). In a study performed by Trump et al. (11), 
1527 cases of non-racehorses, which were examined in a referral hospital because of injuries to the 
SL, the digital flexor tendons and associated structures were evaluated according to their athletic 
type of use. The SL was the most common affected structure in pleasure horses, dressage horses and 
show jumpers. The SDFT was most commonly affected in eventing horses. When evaluating front and 
hind limbs separately in pleasure riding horses, the most commonly affected tendons in the front 
limbs were the SDFT, the SL and the accessory ligament of the deep digital flexor tendon (AL-DDFT). 
However in the hind limbs, the SL was far more commonly affected than the SDFT and deep digital 
flexor tendon (DDFT). In dressage horses, the SL was by far the most commonly affected structure in 
both front and hind limbs. The second and third most commonly affected structure in the front limbs 
were the SDFT and the AL-DDFT. In show jumpers and in eventing horses, the SDFT was more often 
affected than the SL in the front limbs, whereas the SL was the more commonly affected structure in 
the hind limbs. The comparative risk for a forelimb to be affected compared to a hind limb was 3.0 
times higher in eventing horses, 2.6 times higher in show jumpers, 1.8 times higher in dressage 
horses and 1.7 times higher in pleasure horses.  Even though different equestrian disciplines place 
different demands on the locomotory system of the horse, these data highlight the fact, that the 
major energy storing tendons, i.e. the SDFT and the SL, are more prone to injury than any other 
tendon structure within the equine distal limb (30). 
 
 
4.4 Mechanisms of tendon injury 
Tendons can suffer from intrinsic (strain) and extrinsic (percutaneous) injury. Extrinsic injuries are 
relatively rare, and are associated with skin lacerations in the majority of cases. Overstrain injuries 
are believed to appear by one of two mechanisms. They can result from sudden overloading of the 
structure, which overwhelms its resistive strength. However, for most of the strain-induced injuries 
in the horse involving the palmar/plantar tissue structures of the metacarpus/metatarsus, clinical 
injury is believed to be preceded by a phase of molecular degeneration. Cumulative fatigue damage 
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weakens the tendon matrix and allows the initiation of clinical tendonitis when submaximal loading 
overcomes the resistive strength of the tendon. 
Several reasons are discussed in the literature as to why the SDFT and the SL are prone to injury and 
how degenerative changes may predispose the tendon to injury. Normal strains in the SDFT recorded 
in vivo are in the region of 3% to 8% at the walk, 7% to 10% at the trot and 12% to 16% in the gallop 
(39). Maximal strain (i.e. percentage elongation) to failure (rupture of the tendon) in the SDFT ranges 
from 12 -21% in vitro (40-42). These data underline the concept that at maximal exercise, the SDFT 
operates close to its functional limits with a narrow safety margin, and thus only minor influences 
may result in tendon injury (43). A study in ponies has shown that the SDFT and the SL are subjected 
to almost the same level of loading during walk and trot exercise in vivo (44). As the ultimate tensile 
force needed to rupture the SL is higher than that for the SDFT (45), the SL may have a larger 
tolerance at faster gaits when peak loads occur.  
In contrast to the SDFT, the primary function of the DDFT appears to be flexion of the distal 
phalangeal joint during the late swing phase of the stride, rather than storage and return of energy 
(46). Correspondingly, in vivo studies have shown that the DDFT experiences lower peak forces and 
strains during locomotion than the SDFT and the SL (44, 47). The muscle of the DDFT contains a high 
percentage of fast twitch muscle fibers and therefore is more susceptible to fatigue. As the DDFT 
stabilizes the metacarpophalangeal joint during hyperextension, fatigue of its muscle destabilizes the 
metacarpophalangeal joint and therefore the SDFT will be subjected to higher strains (47). Several 
studies have indicated a higher risk of tendon injuries at the end of a race, when racing over longer 
distances or over fences (1, 3, 48, 49). 
The strength of a tendon is correlated to the number and size of the collagen fibrils. Collagen fibrils 
increase in size during development and in response to increased physical demands or training (32). 
Intermolecular covalent crosslinks between fibrils also play a role in the tensile strength of tendon. 
The conversion of chemically reducible divalent crosslinks to a network of non-reducible trivalent 
crosslinks is thought to be responsible for a large proportion of the increase in the mechanical 
strength of tendons as they mature. It has been hypothesized by some authors that the mid-
metacarpal region of SDFT in the horse can adapt to exercise during skeletal development, but is has 
little or no ability to do so after skeletal maturity (5, 50). Patterson-Kane et al. were able to show that 
the SDFT and DDFT are mature by two years of age, being made apparent by the replacement of 
immature collagen cross links with no further increase in collagen fibril size and cessation of rapid 
changes in the collagen fibril crimp morphology (51). 
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Epidemiological studies have supported a strong association of age and exercise with the incidence 
of tendon injury in horses (52) and people (53). Direct low-grade mechanical forces around the yield 
point (of the stress-strain curve) led to cumulative fatigue micro-damage of the tendon matrix. In 
long term exercised horses and in aged horses, the non-collagenous component of tendon shows 
changes in the center of the tendon where clinical injury is seen and where there is an accelerated 
loss of glycosaminoglycans (GAGs) and COMP (30). Interestingly another study found increased levels 
of GAGs, as well as increased levels of type III collagen and cellularity in the discolored central core 
region of degenerated superficial digital flexor tendons (54).  
Regional differences in collagen fibril diameter in long term exercised older horses, but not in short 
term exercised or younger horses, have also been detected (55). This higher proportion of shorter 
fibrils within the central region of the SDFT in comparison to controls is assumed to result from 
disassembly of larger diameter fibrils. Additional exercise-accelerated degenerative changes that 
occur inevitably with ageing represent a regional reduction of the collagen crimp angel and length in 
the central core of the tendon (56, 57). Under loading conditions, central fibers are straightened first, 
and hence are most likely to rupture first. Changes in matrix composition, a smaller fibril diameter 
and a reduction of the collagen crimp angel and length are mainly seen in the central core area of 
injured tendons. This offers a possible mechanistic explanation for the generation of core-lesions 
frequently seen in clinical cases of tendon injury.  
Changes in matrix composition present in degenerated tendons suggest an increased rate of matrix 
turnover, which may be an inadequate healing response or an inappropriate cellular response. In 
addition to mechanically induced micro-damage, other etiologies have also been described including 
hyperthermia, hypoxia or, in human tendons, neurogenic (58). Hysteresis refers to the energy loss 
between the loading and unloading cycle of tendon determined from the area between these two 
curves. Hysteresis is usually about 5% in equine tendon (40). Much of this energy is lost as heat and 
results in a temperature increase within the core region of the tendon. In galloping horses, 
temperatures of up to 45°C have been detected and are suggested as a causative factor for 
tendonitis of the SDFT (59). In vitro experiments have shown that tenocytes are much more resistant 
to these temperature increases in comparison to other fibroblast-like cells (60). However, another 
study has shown increased production of pro-inflammatory cytokines in equine tenocytes at 
temperatures above 45° C, which will likely increase the production of matrix degrading enzymes 
(61). Therefore, hyperthermia may still influence tendon matrix quality. The relative poor blood 
supply in tendons limits heat dissipation but may also result in low oxygen levels within the core 
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region of tendons. Low oxygen supply may compromise the synthetic and degradative activity of 
tenocytes. 
Furthermore, the upregulation of matrix degrading enzymes, through over- or under-stimulation of 
tenocytes, may also result in degenerative changes. Several in vitro studies have demonstrated that 
tenocytes under cyclic stretching express matrix metalloproteinases (MMPs), interleukin-1β (IL-1β) 
and prostaglandin E2 (PGE2) (62-64). These studies suggest that the strains experienced by the SDFT 
may cause cells to produce proteolytic enzymes, which will break down the matrix. In a study 
performed by Clegg et al. (65), MMP13 gene expression was elevated substantially in acute and 
chronic tendon injury, whereas MMP1 gene expression was just elevated in acute injury. As in 
studies in man (66, 67), MMP3 gene expression was decreased in acute and chronic tendon injury. 
ADAMTS4, TIMP1 and TIMP2 levels were unchanged compared to normal tendon, whereas 
ADAMTS5 and TIMP3 levels were substantially decreased in acute tendon injury. As MMPs are tightly 
controlled at a number of levels, including synthesis, secretion, activation of the zymogen, 
localization and clearance of the enzyme, such studies do not necessarily reflect the active 
proteinase profile within the tissue. Furthermore they also have important roles in normal 
physiological events in tendon homeostasis and repair. Alternatively, stress shielding of cells due to 
micro-damage, leading to unloading of the damaged fibrils, will alter the cell-matrix interactions. 
Stress deprivation causes increases in expression levels of the collagenase MMP13, alterations in cell 
morphology and pericellular environment (68), and increases in apoptosis (69).  
 
 
4.5 Clinical presentation and diagnosis of tendon injuries 
Clinical tendonitis varies in severity, from individual fibril or fiber slippage, to individual fibril or fiber 
rupture, and ultimately to complete rupture of tendon with progressive involvement of more groups 
of fibers and fascicles. Clinical signs of tendon injury vary considerably depending on the affected 
structure, location of injury within a certain structure, severity and the timing of examination (i.e. 
time from onset of injury and thereby stage of tendon healing). Furthermore, a lack of correlation 
may exist between the severity of injury and the clinical signs, especially lameness present, more 
likely representing the degree of inflammation rather than the degree of damage (30). Depending on 
anatomical location, enlargement of the affected structure may be less obvious in deeper, less 
superficially positioned structures. In acute tendon and ligament injuries nearly all cardinal 
symptoms of inflammation are present. An increase in surface temperature can be the earliest and 
most subtle clinical sign of injury or re-injury detectable by digital palpation, in more superficially 
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located structures or thermography. Sensitivity to direct digital palpation, best done in comparison to 
the contralateral limb, further confirms the affected structure and location. Depending on location of 
the tendon injury, enlargement of the affected tendon may be detectable by digital palpation or by 
macroscopic evaluation of the tendon profile (Fig. 3a). As only enlargement of a tendon may also be 
the end-stage of repair of a previous tendon injury, it should be considered along with other 
inflammatory symptoms in more acute cases. Even though not specific to tendon injury, it is 
accompanied by increased subcutaneous or peritendinous fluid accumulation, detected 
macroscopically by the less defined appearance of subcutaneous positioned structures and again, by 
digital palpation. The degree of lameness varies between affected structures, location within one 
structure, time from onset of injury, severity of injury, type and athletic use and in between 
individuals. In general terms, more acute and severe injuries carry a higher risk of severe lameness. In 
more chronic and mild cases of bilateral tendon injuries as seen in SL desmitis, lameness may not be 
an obvious sign of injury but reduced performance or the ability to shift the weight to the hind 
quarters may be the only clinical symptoms. Complete rupture of the digital flexor tendons or the SL 
is generally accompanied by severe lameness, even though improving relative quickly over time. 
Through the loss in support, complete rupture of the SDFT or the SL leads to pathological 
overextension of the metacarpo-/ metatarsophalangeal joint. In cases of complete rupture of the 
DDFT, the toe of the hoof rises during the stance phase of the affected limb. In certain anatomical 
locations where tendons are enclosed by synovial sheaths, i.e. carpal-/tarsal sheath and the digital 
flexor tendon sheaths, tendon injury involving the outer boarders of the tendon lead to 
tenosynovitis, characterized by increased filling of the sheath. 
The most common imaging modality to confirm a tendon injury, but also to objectively asses the 
severity of injury and to track the stage of tendon healing, is diagnostic ultrasound (Fig. 3b). Cross 
section area of the tendon and defect zone, length of the defect, echogenicity of the defect zone in 
comparison to healthy tendon and fiber alignment during the stages of healing are classical 
parameters recorded. An advancement of the classical ultrasound, even though not widely used, is 
the computerized ultrasonographic tissue characterization (UTC), a system consisting of both 
hardware and software for quantitative evaluation of tendon structural integrity. In UTC, a precision 
instrument along the long axis of the tendon drives a high frequency ultrasonographic probe. 
Transverse images are stored at real time for later processing by compounding contiguous transverse 
images into a 3D ultrasonographic data-bloc, which can be used for tomographic visualization, tissue 
characterization and calculation of lesion size. In selective cases where the suspected injury zone is 
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inaccessible for ultrasound, as in the case of DDFT injury within the hoof capsule, magnetic 
resonance imaging is the diagnostic modality of choice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3a: Macroscopically     Figure 3b: Ultrasonographic image of SDFT tendonitis  
enlarged SDFT   
 
 
4.6 Tendon healing 
Once the peak load on the tendon overcomes its structural strength, there is physical damage of the 
tendon matrix. The damage induces as repair process similar to that found in other soft tissues, such 
as skin, characterized by inflammation followed by fibroplasia. With the onset of clinical injury, the 
acute inflammatory phase begins, in part determined by the severity of the injury and the anti-
inflammatory therapy initiated. The inflammatory phase is characterized by intratendinous 
hemorrhage, increased blood supply and edema, and infiltration of leukocytes, initially neutrophils, 
followed by macrophages and monocytes. In general, the inflammatory phase lasts 1 to 2 weeks. The 
sub-acute reparative or fibroblastic phase starts a few days after the onset of injury, overlapping with 
the inflammatory phase and peaks at around 3 weeks. It is characterized by a strong angiogenic 
response and the accumulation of fibroblasts within the damaged tissue, which are responsible for 
synthesizing the scar tissue. The morphology of the invading fibroblasts differs from that of normal 
tenocytes. They are larger and more basophilic and have large vesicular nuclei, and are thus more 
similar to myofibroblasts than tenocytes (70). The chronic remodeling and maturation phase begins 
several months after the injury. The newly formed collagen in the scar is not as highly cross-linked as 
in normal tendon. Type III collagen, present in low amounts in normal tendon (< 1%), is as high as 20 
– to 30% in tendon scar tissue (70). The significantly greater proportion of type III collagen is believed 
to deleteriously affect the mechanical properties of the tissue (71-74). The previously formed scar 
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tissue is remodeled over the course of several months, being identified by improved fiber alignment 
and conversion of type III collagen to type I collagen (75-77).  
To achieve sufficient structural strength, larger amounts of fibrous tissue are laid down within and 
around the tendon, giving rise to a tendon that is persistently enlarged but which also has greater 
structural stiffness (Fig. 4). Furthermore, the healed tendon fails to retain the biomechanical 
properties of the original tendon prior to the injury (78) due to persistently deficient structural 
organization and composition of the matrix (Fig. 4) (70). A significantly greater proportion of type III 
collagen is just one of the factors contributing to the sub-standard mechanical properties of the 
tissue (71-74). The increase in stiffness reduces the efficiency of the tendon as a spring and 
compromises the performance of the horse (43). Furthermore, the increased stiffness in the repair 
tissue results in increased strain rates in adjacent and relatively undamaged regions of the tendon, 
which are therefore more prone to injury. Besides the insufficient healing response of tendon tissue, 
adhesion formation between tendons and adjacent tissue further compromises function of the 
healed tendon. The hypocellular histological structure, poor blood supply and bradytrophic 
metabolism of tendons are thought to be major reasons for their limited self-healing properties (79, 
80).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Tendon healing one year after SDFT tendonitis in the left front leg of a 11-years old eventing 
horse; the left SDFT is macroscopically enlarged and the defect area still displays discoloration. 
Histologically, a higher cellularity can be seen along with a less well organized ECM and increased 
numbers of blood vessel. 
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4.6.1 Cells involved in tendon healing 
Cells involved in the repair process may originate from different sources within the tendon (e.g. 
resident tenocytes, endotenon and paratenon cells) and from the peripheral circulation. Therefore, 
some authors differentiate intrinsic (81) and extrinsic (82) repair in tendon damage (83, 84). Wong et 
al. have demonstrated that flexor tendon healing is more complex than can be accounted for by the 
intrinsic and extrinsic concepts alone (85). It is now believed that these two mechanisms act 
cooperatively. It is hypothesized that first, fibroblasts and inflammatory cells from the tendon 
periphery, blood vessels and circulation are recruited to the injury site, thereby contributing to 
cellular infiltrate and the formation of adhesions. Thereafter, intrinsic cells from the endotenon are 
activated as they migrate and proliferate at the injury site, recognizing the ECM and giving support to 
the internal vascular networking (86, 87). The origin of the reparative cells remains in debate. Using a 
model of tendon injury in two different chimeric rats, where one group expressed green fluorescent 
protein (GFP) in circulating mesenchymal cells and the other group expressing GFP in the patellar 
tendon, Kajikawa et al. were able to show an initial invasion of circulating mesenchymal cells, 
followed by the activation of local cells, which participate in the proliferative phase and carry out the 
remodeling phase (88). 
 
 
4.6.2 Growth factors involved in tendon healing 
Several growth factors and cytokines are involved in tendon healing (89, 90). The most investigated 
cytokine is transforming growth factor- β (TGF-β) (91). TGF-β belongs to a family of related proteins 
that regulate many cellular processes. Mammalian TGF-β has three known isoforms (TGF-β1, - β2 and 
- β3) and in many instances these isoforms are indistinguishable in their effect on cell behavior. All 
three isoforms are believed to signal through the same TGF-β receptors (TβRI, TβRII and TβRIII) and 
are secreted as latent precursor molecules that require activation, thereby allowing the TGF-β ligand 
to bind to its receptor and activate the intracellular pathway. TGF-β1 is upregulated in the flexor 
tendon/synovial complex in the early postoperative period (92, 93), with TGF-β receptors being 
upregulated after tendon injury and found concentrated along the repair site (94). 
Immunohistochemistry and Western blotting showed low levels of TGF-β in normal, healthy equine 
tendon, but after tendon injury higher levels of TGF-β were detected around the injury site (95). In 
tendon injury, TGF-β recruits fibroblasts and macrophages to the site of injury and induces increased 
proliferation, angiogenesis and up-regulation of MMP inhibitors and collagen expression, as well as 
downregulation of proteinase activity (96). However, its upregulation also has implications for 
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pathological scar formation (97). Connective tissue growth factor (CTGF) is a downstream mediator 
of TGF-β1 signaling and acts as a co-factor in fibrosis (98). In an experimental model, elevated gene 
expression of both CTGF and TGF-β1 was observed in early tendon healing (99). Hepatocyte growth 
factor (HGF) secreted by mesenchymal cells, activates its biological activity after proteolytic cleavage 
through its receptor c-Met. In an Achilles tendon model, HGF was implicated as inhibiting TGF-β1-
induced fibrosis by reduction of type III collagen expression and decreased expression of α-smooth 
muscle actin (100). Fibroblast growth factors (FGFs) are a family of related polypeptides. Basic 
fibroblast growth factor (bFGF/FGF2) is found in early wound healing and is known to have a role in 
fibroblast chemotaxis, proliferation and angiogenesis. It has also been shown to be present in 
uninjured as well as repaired flexor tendons (101-103), even though its role in tendon healing 
remains unclear. In vitro bFGF causes tenocyte proliferation and type I collagen synthesis (104). 
Transfection of bFGF into damaged and repaired tendons increased tendon healing and strength 
(105). Furthermore Thomopoulos et al. found increased vascularity and cellularity in healing flexor 
tendons treated with bFGF (106). Insulin-like growth factor-1 (IGF-1) is one of three single chain 
polypeptides belonging to the insulin-like growth factor family (IGF-1, IGF-2, Insulin). Beside its role in 
wound healing, IGF-1 is expressed in uninjured flexor tendons (107) and is upregulated after tendon 
injury and repair (99). In vitro IGF-1 and IGF-2 stimulated proteoglycan, collagen and non-collagen 
protein synthesis in flexor tendon-derived cells (108). In another in vitro study by Herchenhan et al., 
IGF-1 supplementation of engineered human tendon tissue imparted a stimulating effect on fibril 
diameter and the expression of several genes including collagen, tenomodulin (TNMD) and scleraxis 
(SCX) (109). In a collagenase-induced model of flexor tendonitis, intralesional injection of 
recombinant human IGF-1 improved cell proliferation and collagen content as well as a trend toward 
increased stiffness of healing tendons in horses (110). Vascular endothelial growth factor (VEGF), 
present in several isoforms, shares around 20% amino acid homology with platelet derived growth 
factor (PDGF) (111). Their biological activity is exerted over three tyrosine kinase receptors, and the 
bioavailability depends on the isoform binding to the receptor. The up-regulation of mRNA 
expression of VEGF during the early stage of flexor tendon repair suggests some type of involvement. 
In an Achilles tendon model, VEGF gene therapy increased TGF-β gene expression and exogenous 
VEGF appears to increase tensile strength (112). VEGF is an important angiogenic factor, which plays 
a role in tendon rupture, healing and development (113). 
Bone morphogenic protein (BMP) and growth and differentiation factor (GDF) belong to the same 
superfamily as TGF-β. Several BMPs/GDFs appear to play a role in tendon biology. Animal models 
with genetic mutations of BMP14 (GDF5), BMP13 (GDF6) and BMP12 (GDF7) have shown altered 
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Achilles tendon phenotype (114-116). GDF8 (Myostatin) has been shown to be expressed in tendons. 
Mice deficient in GDF8 have weaker, hypocellular, and more brittle tendons (117). BMP12 enhanced 
tendon healing by increased synthesis of type I and III collagens, resulting in increased tensile 
strength (118, 119). In an Achilles tendon transection model, BMP12 was highest at 1 week and 
declined over the 8 weeks study period (120). Lee et al. successfully utilized BMP12 in order to 
differentiate MSCs into tendon-like tissue for the purpose of tendon reconstruction (121). In a study 
by Tan et al. BMP14 improved tendon repair, tenogenic differentiation, increased scleraxis and the 
ratio of type I to type III collagen in MSCs (122). Epidermal growth factor (EGF) plays an important 
role in regulating cell growth, proliferation and differentiation through its receptor EGFR. Tsubone et 
al. showed increased expression of EGF after canine flexor tendon repair in inflammatory cells 
surrounding the repair site (93). Platelet derived growth factor (PDGF) is a dimeric glycoprotein 
composed of two chains (AA or BB) or a combination of the two chains (AB). The five isoforms are 
known to activate cellular responses through two different receptors (PDGFR-α, PDGFR-β). In canine 
derived flexor tendon cells PDGF-BB increased cell proliferation and collagen production in vitro 
(106). In contrast, no changes in cell proliferation could be observed in equine flexor tendon-derived 
cells treated with PDGF-BB, although increases in type I collagen production were demonstrated 
(123). Gene transfer of PDGF had a more pronounced influence on type I collagen production as 
compared to gene transfer of VEGF in rat tenocytes in vitro (124). The neutropins include the nerve 
growth factor (NGF) and the brain-derived neurotropic factor. Their receptors (TrkA, TrkB, p75) have 
been identified in tenocytes derived from human Achilles tendon (125). Berglund et al. were able to 
show that NGF was present in rabbit flexor tendon and sheath, but its expression was not increased 
during flexor tendon repair (126). 
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4.7 Treatment of tendon injury in the horse 
The ultimate goal of any treatment and management program is to maximize the chances for a 
tendon to repair with adequate strength and elasticity for a return to a similar level of performance, 
along with the lowest risk for re-injury within an appropriate period of time (127). 
It was in 1964 that Asheim described the common treatment of tendon and ligament injuries (128). 
These basic principles of cooling, support and rest remain integral parts of what is generally accepted 
and still widely used as the conventional treatment for tendonitis in the horse in many equine 
hospitals. Cold therapy in the inflammatory phase acts anti-inflammatory and analgetic largely 
through vasoconstriction, decreased enzymatic activity, reduced formation of inflammatory 
mediators and nerve conduction. A supportive bandage reduces inflammation and edema by 
increasing interstitial hydrostatic pressure. In more severe cases with complete disruption of a flexor 
tendon, the supportive bandage can be complemented with a splint or cast to support the 
metacarpo-/metatarso-phalangeal- or the coffin joint. For further reduction of the overwhelming 
inflammatory phase as well as for analgesia and thereby the well-being of the horse, non-steroidal 
anti-inflammatory drugs are used. Systemic steroids are thought to be more anti-inflammatory than 
non-steroidal anti-inflammatories but inhibit fibroplasia and hence repair of the tendon. A further 
risk of systemic steroids in the horse is the induction of laminitis. For local anti-inflammatory action 
20% medical grade dimethyl sulfoxide (DMSO) is used topically as a dressing of the bandage. What 
was formulated as rest for the horse represents an exercise rehabilitation program based on the 
severity of the initial injury and the progressing ultrasonographic appearance of the lesion. 
Depending on the initial trauma to the tendon, the rehabilitation time period varies from between 6 
and 12 month, and even longer in very severe cases. At the basic level, conventional therapy aims to 
alleviate the overwhelming inflammation, prevent adhesion formation and exert a positive influence 
on scar tissue remodeling. It has been reported that 23-67% of horses with tendon injury treated 
using conservative methods will re-injure their tendons within 2 years of the original injury (129, 
130). 
The extended period of convalescence, the limited quality of the repair tissue and the high risk of 
relapse, have stimulated interest in the development of new strategies for the treatment of 
tendonitis in the horse. So far, most treatment regimens have failed to prove efficacy or were at least 
not superior to conventional treatment. Intralesional therapies, including polysulfated 
glycosaminoglycans (PSGAGs) (131, 132), hyaluronic acid (HA) (133, 134) and beta-
aminopropionnitrile fumarate (BAPN) (135) have been investigated as alternative treatments to 
improve tendon healing. PSGAGs inhibit collagenase, MMPs and the activation of macrophages (43), 
Introduction 
 
 
 
 
25 
but have shown no effects on proteoglycan production by fibroblasts (132). However, although one 
study reported a success rate of 76% for return to athletic function for horses treated with PSGAGs 
compared to 46% for control horses (129), no difference between treated and control horse could be 
found in another study (130). The use of intralesional HA failed to improve outcome when compared 
to control animals (130). In contrast the use of intrathecal HA decreased the inflammatory cell 
infiltrate, intralesional hemorrhage and intrathecal adhesion formation (133, 136). BAPN inhibits the 
lysyl oxidase enzyme which is responsible for the formation of collagen crosslinks and thereby would 
allow for more normal parallel fiber arrangement. With the use of BAPN, a normal ultrasonographic 
appearance of clinically injured tendons was seen at 20 weeks post treatment (137). An in vitro study 
revealed reduced collagen synthesis of equine tendon-derived fibroblasts under the influence of 
BAPN. The authors therefore concluded that BAPN might delay tendon healing (135). Yamamoto et 
al. compared intralesional BAPN and HA in a collagenase-induced injury model in rabbit Achilles 
tendon. Whereas a positive effect of HA on fiber diameter was detected, this was not the case for 
the BAPN treated group (138). One clinical study reported a decrease in the re-injury rate for the 
affected limb being treated with intralesional BAPN (16% re-injury rate) compared to intralesional 
PSGAGs or HA and systemic PSGAGs (42.5 to 44.4%) over a 2 year observation period (130). 
Extracorporeal shock wave therapy has demonstrated significant improvement in prognosis over 
conservative treatment for chronic hind limb proximal suspensory ligament desmitis (139, 140), most 
likely through induction of analgesia (141). However, besides studies in laboratory animals, where 
histological differences in granulation tissue where found (142), no scientific evidence for its 
application in the assistance of equine flexor tendon healing have been reported. Surgical treatment 
strategies are equally controversial. Percutaneous tendon splitting was initially advocated to treat 
chronic cases of tendonitis as early as 1931. Later, investigators found that tendon splitting resulted 
in increased trauma and granulation tissue production, no alterations in collagen production and 
continued lameness (143, 144). More recently, tendon splitting has been revisited as an effective 
technique for the management of acute, rather than chronic tendonitis, where it was thought to 
allow evacuation of the intratendinous hematoma and edema, reduce lesion size and improve 
collagen fibril orientation (145). To date, controversy exists between investigators as to the long-
term effectiveness of tendon splitting because the quality of repair and return to race form are 
variable and often not superior to other treatment methods (145). Desmotomy of the accessory 
ligament of the SDFT (ALSDFT) to treat SDFT tendonitis is also considered controversial. The rationale 
behind this desmotomy is to increase the involvement of the SDFT muscle and thereby reduce the 
peak loads on the SDFT at full weight bearing in the remodeling phase of the healing process when 
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the animal returns to work (146). A later in vitro investigation into the biomechanical effects of 
desmotomy of the ALSDFT determined that the strain and metacarpophalangeal joint hyperextension 
increased following transection of the ALSDFT, which would appear to be counterproductive (147). A 
study reported by Gibson at al. found that horses after desmotomy of the ALSDFT were more than 
1.3 times more likely to race on 5 or more occasions, but were also more than 5.5 times more likely 
to experience SL injury (148). 
The poor clinical outcome associated with tendon injury and the limited capacity for regeneration of 
injured tendon have resulted in a growing interest in the use of tissue engineering approaches for 
tendon therapy in both man and animals (149). Furthermore, biologically based strategies aimed at 
increasing cell activity and production of extracellular tendon matrix proteins are growing in 
popularity (150, 151). 
 
 
4.7.1  Growth factors and cytokines for tendon healing 
Different growth factors have been observed in tendon and during tendon healing, and have been, at 
least in part, evaluated for their potential to improve tendon healing. IGF-1 is a mitogen that 
stimulates ECM synthesis. Additional benefits are an increased DNA and collagen synthesis, improved 
echodensity of tendon and a trend towards increased stiffness (110). Currently, no clinical studies 
exist in which the re-injury rate after IGF-1 treatment has been examined. Therefore, further studies 
are needed before the use of IGF-1 can be recommended for clinical cases of tendon injury. TGF-β 
has also been considered for intralesional treatment, but clinical evidence is lacking. In a prospective 
3-year study, 10 horses with SDFT tendonitis and 1 horse with SL desmitis were treated with TGF-β1. 
Up to 60% of horses had palpably enlarged tendons in the treatment area. All horses returned to 
their previous level of athletic use, but 40% injured the contralateral, untreated limb. This led to an 
overall re-injury rate comparable to conservative treatment, even though it is known that many, if 
not all, strain induced tendon injuries in race horses have bilateral components (30, 152). Besides the 
use of single growth factors, mixtures of growth factors are under mostly clinical evaluation. 
Treatment with intralesional bone marrow aspirate has been evaluated for the treatment of SL 
desmitis, where a success rate of 84%, with these horses returning to full work has been reported 
(153). Bone marrow is a rich source of growth factors (154) but contains very few MSCs (1 in 104 
nucleated cells). Hence this treatment more closely resembles a growth factor treatment. Over the 
past decade, Platelet rich plasma (PRP) has gained increasing attention in human orthopedic sports 
medicine as well as in the treatment of equine tendon injury. PRP can be created using centrifugation 
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or through gravity filtration of autologous blood. The α-granules of the platelets contain, among 
others, PDGF, TGF-β, VEGF, IGF-1 and EGF, which are released on platelet activation. The definition 
for PRP in the literature is somewhat variable. In literature concerning human medicine, any 
autologous plasma with a platelet concentration above baseline blood values (155) or a 
concentration of at least two times (156) to more than five times (157) above baseline values is 
defined as PRP. In equine medicine PRP is generally accepted to have a platelet concentration of at 
least two to four times above plasma level. Preparations with lower platelet concentrations are 
therefore termed autologous conditioned plasma (ACP). A novel approach to better characterize PRP 
preparations and to allow for better comparison of published results is by using the PAW 
classification system, taking the absolute numbers of platelets, the manner in which platelet 
activation occurs and taking the presence and/or absence of white blood cells into account (158). 
Beside its use in oral and maxillofacial surgery to accelerate peri-implant and soft tissue healing (159-
163), PRP has also been investigated for regeneration of bone (164, 165), cartilage (166) and 
ligament (154). PRP has been demonstrated to enhance the expression of COL1A, COL3A and COMP 
in equine tendon explants, with no associated increases in MMP3 or MMP13 (167). In a surgically 
induced model of equine tendinopathy, the intralesional administration of PRP resulted in 
modulation of composition, organization and biomechanical properties (168). Also, reports on small 
case series suggest efficacy of intralesional PRP (169) although long term clinical data on a sufficient 
number of cases have yet to be published.  
The acellular matrix of porcine urinary bladder submucosa (ACell™) is marked as an additional 
therapy for tendon injury. It has been proposed that ACell™ delivers extracellular matrix components 
and growth factors to the damaged region of the tendon and may attract MSCs to the site through 
the release of bioactive breakdown products (170). Beside anecdotal reports that this treatment 
improves tendon healing, one study investigating ACell™ usage following collagenase induced 
tendinitis failed to prove any positive effects of this treatment (171). Autologous conditioned serum 
(ACS), marked in veterinary medicine under the trade name IRAP™, was initially introduced on the 
marked to treat equine osteoarthritis. Through a conditioning process, autologous leukocytes in the 
presence of chromium sulfate coated medical grade glass beads produce the anti-inflammatory 
mediator interleukin-1 receptor antagonist (IL-1Ra).  An increase of a 140-fold of the concentration of 
IL-1Ra through the conditioning process was proven in human subjects (90). After sterile filtration, 
the ACS is then injected into the affected joint, were the competitive receptor antagonist is thought 
to block the inflammatory cascade. Besides the increase in IL-1Ra through the conditioning process, 
levels of FGF2 and TGF-β1 were increased up to 750% and 182% in human subjects (87). It is the 
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increase in growth factors that has encouraged the use of ACS to treat soft tissue injuries. Treatment 
of muscle injuries in both mice and humans by local administration of ACS resulted in accelerated 
muscle regeneration (87,89). Dahlgren et al. evaluated the effect of ACS on normal tendon explants. 
They found no significant difference in GAG, COMP or type I collagen between normal equine serum 
and ACS treated cells (172). Easter and Watts presented a case series of 272 horses treated with ACS 
for proximal suspensory desmitis at the 60th Convention of the American Association of Equine 
Practitioners in Salt Lake City, Utah in 2014. They reported a high success rate combined with a 
shortened convalescence period, but included just cases with no or only minor fiber disruption, and 
provided no control group (173).   
Experimental evidence has shown that fetal tissue in the early mid-gestational phase responds to 
injury in a fundamentally different manner than does adult tissue (174). In general, fetal wound 
healing occurs at a faster rate and in the absence of scar formation. In addition to skin, fetal articular 
cartilage, nerve and bone have demonstrated the ability to heal without scarring in experimental 
models (175-181). Flanagan et al. found evidence for scar-less healing also in fetal sheep tendon 
(182). It is widely believed that the differential expression of growth factors and cytokines in fetal 
tissue in the early gestation period compared with that in the late gestational period and in adult 
tissue plays an important role in this distinct healing process (174, 175, 183). Interestingly, 
mechanical and chemical factors used in many tissue engineering strategies are those identified in 
adult tendon homeostasis and healing, even though these factors direct adult tendon healing 
towards scar formation rather than tissue regeneration (184). A new paradigm is to use embryonic 
developmental factors as cues to promote tendon regeneration, although the majority of soluble 
factors regulating embryonic tendon development are unknown (31). It is thought that TGF-β 
signaling plays a central role in the induction of skeletal progenitors toward the tendon fate (185). 
 
 
4.7.2  Cell-based tendon therapy 
The prospect of regenerating damaged or diseased tissues has led to a vast variety of cell-based 
therapeutic strategies. A sub- or side-population of precursor cells (tissue-specific progenitor cells) 
that are used to replenish cells lost because of natural turnover and to aid in post injury repair has 
been identified in most tissues (149) and may represent an interesting cell source. Notable examples 
are the muscle satellite cells (186-189), multipotent cells from the brain (187), cartilage (189, 190), 
trabecular bone (191), placenta (192), liver, lung, spleen, thymus and pancreas  (189). Multipotency 
has also been shown for cells derived from tendon (193), but the exact side for these cells within the 
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tendon is not known. Fibroblasts derived from tendon or other sources are under investigation as 
well (194). However, the potential formation of a secondary lesion in the tendon at the donor side, 
along with differences in cell characteristics that arise in different tendons and regions of tendon 
(195) may not be ideal. Dermal fibroblasts, which were shown to be capable of functionally bridging 
a tendon defect and to have similar histological and tensile properties to a tenocyte seeded scaffold 
(196), behaved differently from tenocytes in vitro (197). 
Stem cells have two basic characteristics; they are able to continually self-renew and are capable of 
differentiation into multiple specialized cell types (198). Furthermore stem cells have been shown to 
produce several growth factors, interleukins and other cytokines (199). Different stem cell sources 
have been considered in the horse. Embryonic stem cells (ESCs), even though exhibiting real 
pluripotency, carry the disadvantage of being allogenic and being associated with the risk of 
teratoma formation (200-205), although teratoma formation has so far not been shown for equine 
ESCs. The risk for teratoma formation may be even higher in induced pluripotent stem cells (iPSCs) 
(206). 
Within the equine orthopedic field, MSCs have been used experimentally and in limited numbers in 
clinical cases to treat subchondral cystic lesions, for bone-fracture repair (207) and cartilage repair 
(208, 209). However, the most common clinical application of MSCs is in the treatment of overstrain-
induced tendon injuries. The predominant cell type currently in use are autologous MSCs, which can 
be harvested in sufficient numbers from bone marrow (sternum, tuber coxae), adipose tissue and the 
umbilical cord (210, 211).  
Critical to tendon tissue engineering is the induction and guidance of stem cells towards the tendon 
phenotype. Several key factors can influence the differentiation of MSCs. Of those, the mechanical 
environment, contact with resident cells and the extracellular matrix, as well as soluble growth 
factors, are of special importance. The paracrine signals that fine-tune MSCs to the unique tenocyte 
fate during normal development are virtually unknown, but they appear to involve FGFs (212) and 
key members of the TGF-β family, such as GDF5, 6 and 7 (213). Several studies have explored the use 
of various growth factors promoting tenogenesis (95, 121, 214, 215). Just recently TGF-β2 was 
identified as a potent tenogenic factor for tendon progenitor cells and MSCs (95). Hoffmann et al. 
demonstrated the expression of tenogenic markers in vitro and tendon tissue formation in vivo with 
transfected MSCs expressing SMAD8 and BMP2 (216). In line with the mechano-active nature of 
tendon, it seems that mechanical forces play a role in promoting tenogenesis. A number of recent 
studies have emphasized the importance of mechanical regulation of tenogenesis using MSCs (217-
221). Other studies have demonstrated positive effects of mechanical stimulation on cell 
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proliferation, type I collagen production and cell alignment of MSCs (222). In comparison to 
adipogenic, osteogenic and chondrogenic differentiation, little is currently known about the precise 
signaling pathways and molecular mechanisms responsible for the differentiation of MSCs into 
tendon fibroblasts (223). The current lack of a phenotypic marker for tenocytes in vitro makes it 
difficult to establish a culture system for their generation from stem cells (224) and to determine 
whether MSCs have the ability to differentiate into tendon fibroblasts (225). 
There are a number of experimental animal models, which have demonstrated efficacy of MSC 
implantation over controls, usually using laceration models in rabbits or rats (226-228).  
Characteristics of overstrain tendon injuries in the horse lend themselves for a tissue engineering 
approach based on the fact that lesions are usually core lesions, providing a natural enclosure for 
implantation and are filled with granulation tissue by the time of implantation, which acts as a 
scaffold. Furthermore, neovascularization of the defect area provides nutritional support for the 
implanted cells. Through the intratendinous location of the defect, anabolic factors and mechanical 
stimuli are provided. 
Promising preliminary results were demonstrated following the treatment of tendonitis of the SDFT 
with bone marrow-derived MSCs (BMSCs), where an 18% decrease in the re-injury rate was observed 
as compared to 56% after conventional treatment (229, 230). A shorter post treatment observation 
period (> 1 year for the BMSC group as compared to >2 years for the conventional treatment group) 
is a limiting factor in this study.  
Despite stem cell therapy having proven high potential with no known side effects, the mode of 
action of the implanted cells remains unknown. One of the basic characteristics of stem cells is their 
capability to differentiate into multiple specialized cell types. Furthermore, stem cells have been 
shown to produce several growth factors, interleukins and other cytokines (199). Because of this, 
three distinct mechanisms for their mode of action in tissue regeneration are feasible, (i) the cells 
secrete factors which stimulate the regenerative capacity of the tendon such as VEGF, bFGF or IGF; 
(ii) the cells become integrated into the damaged tendon and differentiate into tenocytes and (iii) a 
combination of (i) and (ii). Whereas the amount of cells is crucial for a reliable paracrine effect, cell 
retention is key for functional integration of the transplanted cells. Therefore, the application format 
will play an essential role in the development of efficient cell-based therapies to regenerate the 
tendon.  
Cell-based therapy to regenerate diseased tendon tissue has shown high potential and has attracted 
considerable interest in both the scientific and clinical communities. As for many of the therapeutics 
presently available, technology and marketing are ahead of laboratory and clinical research. 
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Current techniques used in the clinics are simple and likely to require more sophisticated 
methodologies to optimize efficacy. To optimize the therapeutic concept, unanswered questions like 
the differentiation capacity of the applied cells, the mode of action and most suitable application 
format, need to be answered by further scientific evaluation. Future research will unveil mandatory 
data about cell-based therapy and thereby improve treatment strategies in the horse, other animal 
species and humans. 
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4.8 Experimental models of tendon injury 
A valid model of tendinopathy/tendon injury should replicate the clinical, histopathological and 
functional characteristics seen in the naturally occurring injury. However, no single animal model can 
fully reproduce the naturally occurring situation. Therefore, several animal models may have to be 
used in a concerted effort to study the different aspects of tendon injury and healing. 
Naturally occurring tendinopathy/tendon injury is common in racing dogs and in horses. Even though 
there are obvious anatomical differences between quadrupeds and bipeds, individual animal species 
have naturally occurring strain-induced injuries of specific tendons with similarities to specific human 
tendinopathies. The superficial digital flexor tendon of the horse for example, shows many 
similarities to the human Achilles tendon. As naturally occurring tendon injuries varies significantly 
and are impossible to control, they are not suitable for controlled studies. On the other hand, future 
success in their treatment may stimulate management of tendinopathy in humans. 
Induced tendinopathy models fall into two categories. Mechanical loading is the most frequently 
reported intrinsic factor for tendinopathy and therefore many current animal models have been 
developed based on mechanical overloading of tendon. A second category of model involves the 
introduction of chemicals reported in tendinopathy samples, into normal animal tendon. The most 
commonly used species for induced tendinopathy are rats and rabbits. They are less costly, easily 
available and more biologic tools are available as compared to larger animals. Three different 
methods for mechanical overloading are used. In forced treadmill running, the animal is forced to run 
on a treadmill to mimic tendon overuse. This method has been used to develop tendinopathy in the 
supraspinatus tendon and Achilles tendon of rats.  Increased cellularity, glycosaminoglycan content, 
collagen disorganization, changes in cell morphology, larger cross-section area, a decrease in elastic 
modulus and maximum stress have been observed (231-237).  
Artificial muscle stimulation has been used to induce tendinopathy in the flexor digitorum profundus 
of rabbits and the Achilles tendon of rabbits and rats by electrical stimulation of muscle via surface 
electrodes with the animal under general anesthesia (238, 239). An increase in tear size, tear area 
and tear density have been reported. However, no tenderness, lameness, swelling or reduction in the 
range of motion were noted (238). 
In direct repetitive tendon stretching, direct tendon overloading is induced by stretching the tendon 
repeatedly and directly with a single application of sub-failure cyclic load using an external device 
(240, 241). Inter-fiber space widening, matrix disruption, fiber angulation, thinning and 
discontinuities were accompanied with a marked increase in the mRNA expression of type I, II and V 
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collagen and with an increase in MMP13 and IL-1β expression. However, histology showed no 
inflammation up to 3 days post stretching.  
One of the limitations of the artificial muscle stimulation and the direct repetitive tendon stretching 
method is the single intervention to induce tendon damage, which therefore does not mimic the 
more gradual course of development of overuse-induced tendinopathy. 
The intratendinous injection of chemicals is used to establish animal models of tendinopathy, using 
chemicals, which have been observed in clinical samples of tendinopathy. Chemicals which have 
been used to induce tendon injury animal models include collagenase, cytokines, PGE1, PGE2 and 
fluoroquinolone. 
An intratendinous injection of collagenase has been widely used to produce lesions in the SDFT, the 
DDFT, the Achilles tendon, patellar tendon and the supraspinatus tendon in horses, rabbits and rats 
(110, 242-246). In rabbit patellar tendon the injection of collagenase increased angiogenesis, hyper 
cellularity, focal fibrosis and collagen-bundle disarray. The cross sectional area of the tendon was 
increased and collagen content significantly decreased at 4 weeks (243). In the horse, core lesions 
within the SDFT were induced with collagenase and were characterized by extracellular matrix 
damage, loss of spindle-shaped fibroblasts, increased expression of type III collagen and decreased 
mechanical properties (110, 245). 
Stone at al. (243) injected cytokines and cell-activating factor (CAF) into rabbit patellar tendon. There 
was no change in tendon cross-sectional area and the matrix appeared intact. Only a transient 
increase in cellularity was observed, along with a significant decrease in the ultimate load at 16 
weeks. As the cytokine and CAF mixture is not present in naturally occurring tendon injury, the 
validity of this model is questionable. 
The intratendinous injection of prostaglandins to induce tendon injury is based on the increased 
expression of prostaglandin E2 (PGE2) and cyclooxygenase (COX) -2 in clinical samples of tendon 
injury, the increased production of PGE2 during exercise and the increased production of COX-1, -2 
and PGE2 in human tendon fibroblasts after repetitive mechanical loading in vitro (64, 247-249). 
Repeated injections of PGE2 in rabbit patellar tendon led to focal hyper cellularity and matrix 
degeneration (250). Sullo et al. reported an inflammatory response followed by degenerative 
changes including increased vascularity, cellularity and fiber disorganization after PGE1 injection into 
the peritenon (251). As PGE1 has not been demonstrated in naturally occurring tendinopathy, the 
reliability of this model is uncertain. Fluoroquinolone antibiotics have been implicated in the etiology 
of tendinopathy in humans. Especially the Achilles tendon, but also the biceps brachii, the 
supraspinatus and extensor pollics longus tendon have been affected (252). In fluoroquinolone-
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associated tendinopathy, hypercellularity, increased GAG content and mucoid degeneration was 
detected. Furthermore, increases in tendon thickness and hypoechogenic areas in ultrasonographic 
imaging were noted (253, 254). In dogs treated orally with ciprofloxacin for 5 days, the amount of 
type I collagen, elastin, fibronectin and β1-integrin was decreased in the Achilles tendon (255). As 
fluoroquinolones are not involved in the majority of tendinopathy cases, their use to induce a model 
of tendinopathy remains questionable. 
The collagenase induced tendon injury model is the most commonly used model in the horse. A 
major limitation of this model is due to the strong inflammatory response that extends the 
peritendinous tissue, either due to leakage of the collagenase through the injection site or because it 
causes a melting tendonitis that erodes from the center of the tendon outwards, and thus destroys 
the superficial tendon layers and the paratenon. Because of this, the precise location, size, shape and 
volume of the core lesion are difficult to control. Surgical models of tendon injury have been 
explored sporadically as alternatives to enzymatically induced tendon injuries in horses (256-258), as 
well as in rabbits, sheep and dogs (259, 260). Such models relied on either surgical removal of a 
segment of the tendon, by incising the paratenon and the outer surface of the tendon, or on 
complete transection of the tendon. Quite recently, a new model of tendon injury within the SDFT of 
horses has been established (261), which is thought to overcome the limitations of the collagenase-
induced injury, as well as other existing surgical models. Under general anesthesia and 
ultrasonographic guidance, a synovial resector is advanced longitudinally in the metacarpal region of 
the SDFT creating a core lesion. The surgically created core lesion is further advanced by a 
postoperative exercise program. Even though this model does not mimic every aspect of naturally 
occurring tendon injury, it has proven to be suitable for evaluating the effect of intralesional injection 
of PRP to stimulate tendon healing (168).  
The use of animals for experimentation raises many ethical concerns about the animal welfare. To 
allow for informed scientific and animal welfare decisions, experiments must have the clear objective 
of improving the welfare of man and/or animals, and the researchers need to constantly keep animal 
welfare at the forefront to ensure humane treatment of all animals. Following the principles of the 
three Rs (replacement, reduction and refinement) many basic research questions may be possible to 
answer with in vitro experiments, especially as new culture formats become available, more closely 
resembling the in vivo environment and therefore generating more reliable data. 
 
 
Introduction 
 
 
 
 
35 
4.9 In vitro cell culture of tendon-derived fibroblasts 
Cell culture systems provide many advantages to address different research questions. They not only 
enable monitoring of the exact response of cells to different treatments, but also allow for the 
characterization of a specific cell type. The expansion of differentiated tenocytes in vitro is a useful 
approach to analyze tendon healing and to develop tools to support tendon repair with the use of 
tendon tissue engineering strategies (262). Tendon-derived fibroblasts can be isolated from native 
tissue by explant culture (167, 172, 262-264) or by collagenase digestion (265-271). A more recent 
study revealed a higher cell yield beside a faster time interval for cell isolation using enzymatic 
digestion compared to cell migration from explant culture. Interestingly, type I collagen expression 
was higher in cell cultures using enzymatic digestion, whereas decorin expression was higher in cell 
cultures generated from cell migration (272).Tendon-derived fibroblasts in monolayer culture 
typically exhibit a spindle shape, fibroblast-like appearance, making it impossible to differentiate 
tendon-derived cells from other fibroblastic cells. Therefore characterization of tendon-derived 
fibroblasts in vitro is carried out by gene expression analysis and identification of ECM proteins, like 
decorin and COMP. 
 
 
4.9.1 Gene expression markers of tendon-derived fibroblasts 
There is a paucity of data regarding molecular markers that identify the phenotype of the tendon 
cell. Type I collagen (COL1A2), the major component of the extracellular matrix of tendon is 
expressed in a large variety of tissues and cell types and is therefore not specific to tenocytes. The 
same is true for type III collagen (COL3A1), which is known to be upregulated during tendon healing, 
but again is not specific to tendon tissue. Even though type II collagen (COL2A1) is present in tendons 
(265), especially in locations of where compressive forces act, it is recognized, together with type X 
collagen (COL10A1) and the transcription factor SOX9 as being representative for chondrogenic 
differentiation (190). The transcription factors scleraxis (SCX), Six2, Fibin, Mohawk, Erg1 and Erg2 
have been identified in tendon progenitors (273-277). Of these, the basic helix-loop-helix 
transcription factor scleraxis has been highlighted as a specific marker of tendon progenitors (278-
281). Scleraxis plays essential roles in mesoderm formation (282) and marks the tendon progenitor 
population that forms the fourth somatic compartment the “syndetome”, and is continuously 
expressed through differentiation into the mature tenocyte and ligament cells (279, 283). The classic 
ERK MAP kinase pathway has been identified as playing an important role in the regulation of SCX 
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gene expression by FGF signaling (284). SCX null mutant mice have been shown to have distinct 
tendon defects and tenogenic differentiation is inhibited (278). 
Besides being discussed as a marker for tendon progenitors, scleraxis has been proposed as a tendon 
specific marker by several authors (275, 279, 285). Lejard et al. were able to show that scleraxis 
activates COL1A1 gene expression in tendon fibroblasts (223). Espira et al. and Maeda et al. could 
show within rat cardiac fibroblasts, myofibroblasts and in Achilles tendon-derived fibroblasts from 
transgenic mice, that SCX gene expression was dependent on TGF-β signaling and that upregulation 
of SCX led to increased COL1A2 gene expression (214, 286). Furthermore scleraxis regulates the 
expression of tenomodulin (TNMD), another potentially tendon specific maker (267). As SCX is 
expressed in other skeletal lineage cells such as muscle, cartilage and bone, some authors question 
its use as a tendon specific marker (224, 225). 
Tenomodulin has been reported to represent a good phenotype marker for tendon fibroblasts (267, 
287) and is claimed to be a selective tendon gene (225). Mice lacking tenomodulin have tendons with 
a disrupted fibril structure and exhibit severely reduced tenocyte proliferation (288). The soluble 
form of tenomodulin, containing the C-terminal ChM-I like domain, inhibits the proliferation, 
migration and tube formation of vascular endothelial cells (289). Tenomodulin is a type II 
transmembranous glycoprotein that is preferentially expressed in dense connective tissue, including 
tendons, ligaments and the eye (cornea and sclera), but low levels of mRNA transcripts have also 
been identified in muscle, thymus, hearts, liver, spleen, nervous tissue, lungs, cartilage and dermis 
(287, 290-295). The high expression of tenomodulin compared to different other tissues is fading 
when cells are cultured in 2-D systems (69), questioning its use as a tendon specific marker. 
Irrespective of this, Oshima et al. claim that the combination of scleraxis as an early marker and 
tenomodulin as a late marker should enable clarification of the molecular mechanisms underlying 
tenocyte differentiation and tendon regeneration (289). 
Tenascin has been employed as a tendon marker, although it is also expressed in cartilage and nerve 
(224, 294, 296). Tenascin-C (TNC) is an anti-adhesive ECM protein and present in musculoskeletal 
regions that are transmitting mechanical forces from one tissue component to another (297). 
Tenascin-C contains a number of repeating fibronectin-III domains, and following stress induced 
unfolding of these domains, it also functions as an elastic protein (298, 299). The expression of TNC is 
regulated by mechanical stress (300).Tendon regions with a fibrocartilagenous phenotype that are 
subjected to compressive loads have been shown to have higher levels of TNC (295, 301, 302). 
Isoforms of tenascin-C in degenerated tendon were suggested to potentially stimulate tenocyte 
proliferation (303). Tenascin-C may also play a role in collagen fiber alignment and orientation (304). 
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As many of the key matrix genes are expressed in a variety of mesenchymal tissues and therefore are 
not sufficiently discriminatory (265), there are currently no absolute specific molecular markers that 
can be used to characterize tenocytes (305). Some authors therefore recommend the use of a panel 
of marker genes, such as COL1, SCX and TNC, to identify the tendon cell phenotype from other 
mesenchymal tissues (265). Besides the use of more or less specific marker genes, histological 
analyses and mechanical testing are used to verify the success of tendon tissue engineering 
interventions (306). 
 
 
4.9.2 Phenotypic drift 
Cell dedifferentiation is a common biological process in cultured cells deprived of their in vivo niche. 
For example, bovine articular chondrocytes become dedifferentiated after being cultured in 
monolayer for three weeks and lose expression of type II collagen (307). The same has been shown 
for rabbit articular chondrocytes (308) and chick chondrocytes (309). Already in 1976 Schwarz et al. 
noted, that the loss of differentiated function occurred during prolonged monolayer culture of avian 
tenocytes (310). Extended monolayer culture of tenocytes has been reported to lead to decreased 
levels of type I collagen and decorin with continued passages (311). Other authors have reported low 
expression levels of TNMD, observed as an initial reduction and ultimately leading to a total absence 
over the course of extended culturing (265, 266, 269, 294). Jelinsky et al. described a rapid down 
regulation of tendon selective genes (TNMD and thrombospondin4 (THBS4)) in rat primary tendon 
surface cells and internal fibroblasts grown in 2-D cell cultures suggesting that tendon cells in culture 
rapidly dedifferentiate (225). Studies on avian and rabbit tenocytes have indicated that phenotypic 
drift may manifest at early passages (310, 311). Yao et al. reported a decrease in confluent culture 
cell density, a decline in alamar blue reduction, a change in cell morphology from spindle shaped to 
more rounded, an increase in the ratio of type III to type I collagen and a significant decrease in 
decorin apparent by passage 4. It was therefore concluded that tenocytes in monolayer culture 
display an unstable phenotype and tend to dedifferentiate (312). Additionally Stoll et al., evaluating 
human primary tenocytes isolated from hamstring tendons in 2-D and 3-D cultures, observed a 
significant decline in decorin (DCN), aggrecan (ACAN) and SCX gene expression as well as a decrease 
in COMP in the 2-D cultures. It was suggested that these tendon ECM proteins might therefore act as 
predictive indicators of tenocyte dedifferentiation (262). A lack of appropriate cell-matrix interaction 
(313), cell-to-cell interaction (263, 314) mechanical stimulation (69) are discussed as possible cues for 
tendon cell dedifferentiation. 
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In order to allow for the expansion of cell numbers for tissue engineering approaches as well the 
development of in vitro models to evaluate different treatment modalities, phenotypically and 
functionally stable tenocytes, which maintain a differentiated state, are a mandatory prerequisite. As 
connective tissues are known to have unstable phenotypes and retain the ability to return to an 
earlier stage of differentiation or to transdifferentiate along other cell lineages (193, 315, 316), cell 
culture conditions need to be optimized in order to maintain a tendon phenotype (225) or to allow 
for re-differentiation. 
Maintaining tendon-derived fibroblasts in a differentiated state or to re-differentiate tendon cells in 
vitro has been attempted through the use of different culture formats, the addition of different 
growth factors or through mechanical stimulation. 
 
 
4.9.3 3-D cell culture 
Ideally, cell culture models should reflect the characteristics of the tissue from which they were 
derived, even after being grown in culture for long periods of time (317). Evans and Trail (197) 
observed that tenocytes naturally form 3-D structures during in vitro culture. Recent investigations 
have highlighted significant differences in cellular gene expression in monolayer compared with 3-D 
cultures (268). The 3-D cell culture methods are thought to more closely mimic the in vivo cellular 
environment (268, 318) and represent a possible means by which to stabilize the tenocyte 
phenotype, thereby providing more intimate cell-cell and cell-matrix contacts compared with 
monolayer cultured tenocytes (263). The ECM transduces physiological signals to the cells through 
integrins, which not only regulate cell growth and proliferation but also cell differentiation and 
matrix remodeling (319). Sawaguchi et al. were able to show that the switch from monolayer culture 
to 3-D culture led to an up regulation in certain cell-surface proteoglycans, such as CD44, syndecan-2 
and syndecan-4, which can modulate the response of cells to pericellular matrix molecules and 
soluble stimuli such as growth factors and cytokines (268). In the study by Zhu et al., the authors 
noted a change in cell morphology of tendon-derived fibroblasts in monolayer culture from 
elongated to a more spread out morphology, which was accompanied by a reduction and finally loss 
of TNMD expression. Culturing these dedifferentiated cells on micro-grooved silicon membranes 
restored the elongated morphology and TNMD expression (269). Therefore cell shape appears to 
influence, and also reflect the state of differentiation. Cell culture formats should aim to preserve or 
restore the phenotype of tenocytes observed in vivo. 
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High-density 3-D cell cultures devoid of any scaffold material have been utilized for the culture of 
tendon-derived fibroblasts. Schulze-Tanzil et al. cultivated human tenocytes in high-density cultures 
and detected a decrease in type I collagen as well as an increase in SCX expression over time. To rule 
out transdifferentiation of cells to fibrochondrocytes, type II collagen was also measured. However, 
expression levels of type II collagen were found to be comparable to monolayer cultures. Therefore, 
they concluded that this culture format seems to promote differentiation of tenocytes (263). 
Unfortunately, TNMD expression was not investigated.  
Stoll et al. compared high-density 3-D tenocyte cultures and tenocytes cultured on polylactic-
coglycolic acid- (PLGA) scaffolds to normal tendon tissue. In 3-D culture, a morphological shift from a 
tenoblastic cell shape with round nucleus, towards a more elongated tenocyte phenotype was 
observed. Type I collagen expression was increased in all culture formats compared to normal 
tendon, with a decrease over time in 3-D culture. Type III collagen expression was significantly 
increased in high-density 3-D cultures. Decorin expression was higher in 3-D cultures as compared to 
2-D cultures, and COMP expression was only increased in high density 3-D cultures. SCX expression 
levels were reduced in all culture formats as compared to normal tendon, but were elevated in 
monolayer-expanded cells transferred to high-density 3-D cultures. The increase in SOX9 was not 
significant in any culture format. However, no changes in type II collagen protein could be detected. 
β1-intergrin cell matrix receptor gene expression remained mainly unaltered in all culture conditions.  
Based on these results, the authors concluded that high-density 3-D culture as well as PLGA-scaffolds 
might promote tenocyte re-differentiation (262). 
Schneider et al. evaluated the influence of various different culture conditions on the promotion of 
MSC tenogenesis, including different growth factors, the conditioned medium from tenocyte cultures 
and co-culture with primary canine tenocytes. High-density 3-D cultures of tenocytes alone served as 
controls. Although SCX and TNMD expression could be induced in high-density 3-D cultures of MSCs 
under all conditions tested both genes were also expressed in unstimulated controls (264). 
Taylor et al. evaluated gene expression markers of equine tenocytes in tissue samples as well as in 2-
D and 3-D culture formats. Type I collagen expression levels were higher in the 3-D cultures as 
compared to monolayer cultures. SCX expression levels were comparable in both culture systems, 
but remained reduced as compared to normal tendon. TNMD gene expression was not detected in 
either in vitro culture system (265). Because of the short cultivation period of the tendon cells in the 
collagen gel, conclusions should be drawn with caution. 
Another interesting 3-D cell culture format is the gravity-assisted formation of microtissues (MTs) 
through the cultivation of cells using the hanging drop system. MTs combine advantages of 
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engineered tissues, such as the 3-D environment to maintain a differentiated state, and an 
accelerated extracellular matrix production. Applying this technology, the generation of artificial MTs 
from different cell types has been made possible and has included primary human chondrocytes and 
rat hepatocytes, primary human fibroblasts, embryonic sensory neurons, and neonatal rat and 
mouse cardiomyocytes. Even cultures of two or more different cell types displayed cellular 
reorganization into a more in vivo-like morphology (320-324). Mirsaidi et al. cultivated adipose-
derived stromal cells (ASCs) in the MT format (ASC-MT). Besides demonstrating osteogenic 
differentiation in vitro, injection of predifferentiated ASC-MTs into the tibia of an osteoporotic mouse 
model significantly improved trabecular bone quality (325, 326). Up until now, the MT format has not 
been evaluated for the use of culturing tendon-derived fibroblasts.  
 
 
4.9.4 Growth factors 
Embryonic tendon progenitor cell differentiation in vivo is regulated by a combination of mechanical 
and chemical factors (185). Although the mechanisms responsible for the regulation of embryonic 
tendon development remain largely unknown (31), the role of certain growth factors has been, at 
least in part, elucidated. FGF has been identified as playing an important role in the induction of 
tendon progenitors (215) and has been proposed as a likely means through which muscles influence 
tendon formation and survival (327). FGF4 is expressed by myotubes in zones close to the tendons, 
and local application of FGFs in normal limbs upregulates the expression of the tendon marker SCX 
and promotes proliferation of SCX-positive cell progenitors (285). Furthermore, FGFs induce the 
expression of Erg1 and Erg2, which are transcription factors expressed in tendons responsible for the 
maturation of the tendon tissue (275). FGF and TGF-β signaling have been shown to induce early 
tendon markers (215) and Lorda-Diez et al. demonstrated a central role for TGF-β signaling in the 
induction of skeletal progenitors toward the tenocytes (185). Additionally, Schweizer et al. and Seo et 
al. confirmed an essential role for TGF-β2 and TGF-β3 ligands in tendon formation (279, 328). 
There is evidence indicating a role for BMPs in tendon development, but the precise function of 
BMPs in this process is controversial (221). Expression of BMP2, -4 and -5 has been detected in 
developing tendon (329). Macias et al. described BMP7 in developing flexor tendons in chicken limb 
development (330). Regulators of BMP signaling, including Twisted Gastrulation, Dan, Follistatin and 
noggin, are expressed in early tendon blastomas (331). It has been proposed that the BMP antagonist 
noggin, produced by digit cartilage, exerts a positive influence on tendon formation by blocking the 
negative influence of BMP ligands (279). Sclerostin, which may antagonize both BMP and wnt 
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signaling, is expressed at different stages of tendon differentiation (331). In contrast with these 
findings, genetic approaches indicate that a subset of BMPs promote tenogenesis. Structural and 
functional anomalies of the Achilles tendon were reported in mice deficient for GDF5, GDF6 and 
GDF7 (332-334), which belong to the BMP family. Wolfman et al. showed that ectopic injection of 
GDF5, GDF6, GDF7 in rat muscle induces tendon-like tissue (213). Violini et al. claim tenogenic 
differentiation of BMSCs through in vitro exposure to BMP12 (GDF7) as confirmed by enhanced 
TNMD expression. Furthermore a morphologic change from a fibroblast-like to a more tenocyte-like 
phenotype was observed (335). Wang et al. noted the expression of SCX in transfected and BMP12 
expressing MSCs (336). Stimulation of rat BMSCs with BMP12 was reported to induce increased 
expression of TNMD and SCX in both monolayer culture and in collagen scaffolds. Type I collagen and 
TNC expression was also enhanced in cells in 3-D cultures (121). In rat Achilles tendon-derived 
fibroblasts, GDF5 supplementation led to an upregulation of type I and III collagen, TNC, biglycan, 
versican and DCN (337). In rat ASCs GDF5 led to increases in the expression levels of SCX, TNMD and 
TNC (338, 339). However, BMP7 could not significantly influence SCX or TNMD expression in rat 
patella and Achilles tendon cell culture (340). 
Caliari et al. evaluated the effect of different growth factors or combinations thereof, on tenocyte 
chemotaxis, proliferation, metabolic activity and gene expression in equine tendon-derived 
fibroblasts grown on collagen-glycosaminoglycan scaffolds. bFGF and GDF5 resulted in a significant 
upregulation of SCX and TNC expression levels. IGF-1 was capable of significantly enhancing COL1A2, 
COL3A1 and DCN gene expression. Combinations of IGF-1 and GDF5 increased expression levels of 
COL1A2, SCX and COMP (341). Human tenocyte culture in a serum-free 2-D system for 14 days with 
IGF-1 expressed increased levels of DCN but not SCX, TNMD or COL1. In contrast, TGF-β3 resulted in 
increased expression levels of SCX and TNMD, whereas COL1 expression was most pronounced with 
the combination of TGF-β3 and IGF-1. Interestingly, no single factor was capable of restoring the 
phenotype in serum free culture systems (270). The same was true in a study by Schneider et al. in 
which the tenogenic differentiation of canine MSCs was evaluated in high-density 3-D cultures. The 
combination of IGF-1 and TGF-β1 was able to maintain a stable phenotype, although neither was 
effective when used separately. In contrast to the study by Caliari et al. (341) who utilized equine 
tendon-derived fibroblasts, IGF-1 alone was not able to induce DCN expression in MSCs. SCX, TNMD 
and DCN expression levels were highest in high-density 3-D cultures treated with both IGF-1 and TGF-
β1 combined (264).  
Barsby et al. evaluated the influence of the three isoforms of TGF-β on equine ESCs and tendon cells. 
They were able to show that undifferentiated and differentiated ESCs as well as adult tenocytes in 
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vitro express receptors for TGF-β. Furthermore, of the three isoforms, TGF-β3 had the greatest effect 
in terms of upregulating SCX expression in ESCs. Exposure of ESCs to TGF-β3 increased the expression 
of type I collagen, TNC and COMP and by day 7 TNMD. Immunohistochemistry confirmed the results 
of gene expression analysis for type I collagen, TNC, TNMD and COMP with no difference between 
the different isoforms of TGF-β. Although the presence of the TGF-β receptor in equine tendon cells 
was demonstrated in culture, exposure to TGF-β3 did not produce any statistically significant 
increases in expression of any of the tendon associated genes and neither isoform of TGF-β could 
induce changes in protein expression after 7 days of exposure. Interestingly, TNMD and THBS4 
proteins were detected in the absence of mRNA (95). Maeda and co-workers investigated the 
conversion of mechanical force into TGF-β mediated biochemical signals utilizing a transgenic mouse 
strain that expressed the SCX promotor-driven GFP marker. TGF-β1,-2 and -3, and to a lesser extend 
GDF8, induced ScxGFP expression in primary tenocyte cultures isolated from adult ScxGFP mouse 
Achilles tendons. Inhibition of TGF-β type I receptor significantly decreased ScxGFP levels and SCX 
mRNA levels (214). All members of the TGF-β superfamily signal by binding to specific type I and type 
II serine/threonine kinase transmembrane receptors. Upon ligand binding, SMAD proteins are 
phosphorylated and translocated to the nucleus where they function as transcriptional regulators. 
SMAD 2 and 3 account for TGF-β and activin signaling, while SMAD 1, 5 and 8 mediate BMP signaling. 
Therefore, inhibition of SMAD3 signaling reduces the expression of ScxGFP and SCX mRNA levels as 
well (214). 
 
 
4.9.5 Mechanical stimulation 
As stated previously, embryonic tendon progenitor cell differentiation in vivo is regulated by a 
combination of mechanical and chemical factors (185). Little is known regarding the precise 
mechanics involved due to the challenges faced with trying to evaluate the effects of mechanical 
loading on developing tendon in vivo. It is assumed that static and dynamic forces are significant 
contributors to tendon formation during embryonic development (184), but the involvement of 
specific dynamic loading parameters (i.e. strain rate, strain magnitude, duration and frequency) is 
unknown (31). 
Maeda et al. nicely demonstrated the importance of mechanical stimuli on tendon cell viability and 
expression of tendon associated genes in vivo and in vitro through the utilization of the adult ScxGFP 
mice. The acute loss of tensile loading in a complete transection model (of the Achilles tendon) led to 
a reduction in cell viability of around 70% and low ScxGFP expression in the remaining cells. Injection 
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of Botulinum toxin A in the triceps muscle of the ScxGFP mouse led to reversible gradual loss of 
tensile loading, resulting in a decreased muscle force (< 25% of normal) within 3 days, being 
associated with an 80% decrease in the number of tenocytes expressing ScxGFP as compared to the 
control group. Immunohistochemical analysis also showed a significant decrease in the abundance of 
type I collagen fibrils and COMP expression. An increase in cell death, determined through TUNEL-
staining could not be detected in this model. At two weeks post injection of the Botulinum toxin A, 
the tendon began to recover. Numbers of ScxGFP-expressing tenocytes and the deposition of type I 
collagen and COMP increased. The regulating influence of mechanical forces on ScxGFP expression 
could also be demonstrated in vitro. Primary tenocyte cultures from adult ScxGFP mouse Achilles 
tendon showed a decrease in ScxGFP expression over time (<5% by day 6). ScxGFP expression was 
upregulated in tenocytes exposed to shear stress through the use of a microfluidic chamber system. 
Interestingly, as in TGF-β signaling, inhibition of the SMAD 2/3 pathway resulted in decreased 
expression of ScxGFP and SCX mRNA levels in mechanically stimulated tendon cells. As the group was 
also able to demonstrate that mechanical force resulted in an upregulation of TGF-β1 and SCX mRNA 
in vitro, they suggest that mechanical forces regulate SCX expression through activation of the TGF-
β/SMAD 2/3 mediated pathway (214). In addition, Egerbacher et al. outlined the importance of 
homeostatic tension on tendon cell viability. Stress deprivation of rat tail tendon resulted in 
increased caspase-3 mRNA expression, increased positive staining for caspase-3 protein and 
increased apoptosis in tendon cells as compared to cyclically-loaded (3% strain at 0.17 Hz) and fresh 
control samples (69). Furthermore, Huismann et al. could demonstrate an upregulation in type I 
collagen and SCX gene expression in tenocytes culture in BioFlex™ subjected to mechanical 
stimulation as compared to unstimulated human tenocytes. The insertion of a rest period in cyclic 
stretching increased gene expression of type I collagen, SCX and TGF-β (342).  
In line with the mechano-active nature of tendons and the possible influence of mechanical 
stimulation on phenotype and stage of differentiation in tendon-derived fibroblasts, a number of 
recent studies have investigated possible tenogenic effects of mechanical stimulation on stem cells.  
For example, Scott at al. demonstrated the influence of mechanical forces on SCX expression in a 
murine multi-potent cell line C3H10T1/2 grown in 3-D culture. Static load alone already led to a 
dramatic increase in SCX expression in a time dependent fashion. Expression levels of SCX were 
further increased through cyclic loading as compared to static loading. Additionally, SCX expression 
was similarly affected by increased strain levels and cycle number, as well as through the insertion of 
a rest period between each loading cycle (219).  
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Comparisons between 2-D and 3-D human BMSCs cultures grown in collagen gels revealed a higher 
expression level of SCX in the 3-D culture system. Varying the concentration of collagen in the 
scaffold appeared to have no detectable influence on gene expression. Comparing cyclic loading with 
1% elongation at 1 Hz for 30 minutes per day to static loading for a total cultivation period of 7 days 
had no significant impact on the contraction levels of the collagen constructs. Cyclic loading was able 
to maintain the increased expression levels of SCX, which decreased over time in static loading. As 
such, the authors implicated dynamic stimulation as being a key factor in maintaining tenogenic 
differentiation in MSCs (218). 
Raabe et al. investigated the tenogenic differentiation of equine ASCs embedded in a collagen matrix 
under the influence of tensile strain, growth differentiation factors and various oxygen tensions for a 
culture period of 3 weeks. The most optimal conditions were deemed to be an oxygen tension of 
21%, tensile stimulation, and supplementation of GDF5 or -7. Interestingly, no viable cells were 
observed in their control group consisting of ASCs cultured for 3 weeks under mechanical 
stimulation, but without growth factors (343). 
The culturing of tendon-derived fibroblasts and MSCs in 2-D or 3-D systems under mechanical 
stimulation offers the opportunity to explore the influence of mechanical cues, or the combination of 
mechanical and chemical cues, on cell phenotype and differentiation. Furthermore, it allows for 
characterization of the more authentic tenocyte in vitro and the evaluation of different treatment 
modalities for tendon injury in vivo. The 3-D culturing of tendon-derived fibroblasts generally results 
in higher expression levels of tendon related genes and therefore, most likely results in cells with a 
more advanced differentiation status than cells grown in 2-D culture. However, with regards to the 
effects of mechanical stimulation in these systems, it is difficult to draw any conclusions as to which 
settings and conditions are the most appropriate. This is hampered by the fact that there are 
numerous different commercial and custom made mechanical systems available for cell culture with 
a multitude of variables including strain rate, frequency, number of cycles, and rest periods. 
Furthermore, it has to be kept in mind that strains experienced by individual cells is not the same as 
that applied to tendon fascicles or to the scaffold used. Screen at al. were able to show that in 
tendon fascicles exposed to 8% strain, the local strain experienced by the cells did not appear to 
exceed 2% (344). In the BioFlex™ plate an equiaxial strain of 10% resulted in average strain 
experienced by the cells of approximately 3-5% (345). Characteristics of the scaffold material used 
may play a major role in the transfer of forces applied and those experienced by the cells. The 
importance of the properties of the scaffold material should not be underestimated, as interface  
Introduction 
 
 
 
 
45 
properties such as surface/ligand chemistry and density may govern differentiation and cell behavior 
(220).  
Exposing human tenocytes to 3.5% cyclic strain at a frequency of 1 Hz for 2 hours caused increased 
expression of MMP3 and IL1β (62). Cyclical stretching of human tenocytes from 4- to 12% at a 
frequency of 0.5 Hz caused an increased production of PGE2, an inflammatory mediator of 
tendinopathy (64). Therefore, another topic that needs to be further addressed is the upregulation of 
MMPs and other inflammatory mediators triggered by mechanical stimulation and the significance 
thereof.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
 
 
46 
4.10 Aim of the study 
Whilst reviewing the current literature, it became clear that our understanding of tendon 
development, tendon injury and possible strategies to enhance tendon healing is still very limited. 
The expansion of tenocytes in vitro is a helpful approach to analyzing tendon healing and to finding 
tools to support tendon regeneration. Maintaining a differentiated state of the cells under 
investigation is a major prerequisite for enabling meaningful conclusions to be reached. 2-D culture 
techniques are generally used to expand cells to sufficient numbers prior to use in vivo. However, 
there is growing evidence that tenocytes in monolayer culture undergo a process known as 
dedifferentiation and thereby loose some of their basic tenogenic characteristics such as the 
expression of tendon-associated genes and the typical spindle-shaped cell morphology. 3-D cell 
culture methods are thought to more closely mimic the in vivo cellular environment and thereby 
represent a potential means by which to stabilize the tenocyte phenotype and provide more intimate 
cell-cell and cell-matrix contacts compared with monolayer cultured tenocytes. Beside differences in 
cellular gene expression, 3-D culture systems may aid in the histologic identification of tenocytes. 
The hanging drop culture system has the capacity to generate spheroidal microtissues (MTs) 
composed of different cells types. In addition to their ability to enhance the differentiation of certain 
cell types, MTs also have the capacity to act as building blocks for tissue engineering applications. 
However, to the best of our knowledge, equine tenocytes have not yet been cultured as hanging 
drops and as such, their ability to adapt to a 3-D MT environment has not yet been characterized. 
Therefore, based on these criteria, the current Thesis sets out to address the following aims: 
1. Characterize equine adult and fetal tenocytes in the MT format 
a.) Maintain a differentiated state of equine tenocytes in the MT format 
b.) Evaluate the MT format as a system for co-culture of equine tenocytes and MSCs 
2. Evaluate the influence of mechanical stimulation on tenocytes in the MT format and the 
possibility to use MTs for tissue engineering  
 
 
4.10.1 Hypothesis 
The primary premise of the current study is that the maintenance of equine tenocytes in the hanging 
drop culture system will lead to the formation of MTs and subsequently enhance their tenogenic 
potential as determined by gene expression and histological analyses. Furthermore, the introduction 
of chemical and mechanical stimulation, along with MSC co-culture, is envisaged to have a beneficial 
influence on tenocyte differentiation in MTs.
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5 Results 
5.1 Use of biomimetic microtissue spheroids and specific growth factor supplementation to 
improve tenocyte differentiation and adaptation to a collagen-based scaffold in vitro 
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 1: Representative images of equine ASCs (A and B) and equine tenocytes (C and 
D) stained for Alizarin red (A and C) or Oil Red O (B and D) at day 14 after incubation in osteogenic or 
adipogenic differentiation medium respectively. Controls refer to cultures incubated in growth 
medium only. Scale bar = 3.9 mm (A, C), 100 m (B, D). 
Supplementary Fig. 2: Representative high magnification images of hematoxylin and eosin stained 
paraffin wax sections of equine TC-microtissue spheroids cultured for 4 days (A) and 6 days (B) in 
GM. Arrows, identification of elongated tenocytes within microtissue spheroid at day 6. Scale bar 
= 25 m. 
Supplementary Fig. 3: qRT-PCR analysis of COL1A2, COL3A1, SCX, TNMD and SOX9 in equine 
tenocytes cultured in 3D microtissue spheroids for 6 days. In each case, gene expression in equine 
tenocytes cultured in growth medium (GM) alone was compared to cells cultured in either TGF-1 
alone (TGF-1) or tenogenic differentiation medium II (TDM-II). Data was normalized to GAPDH and 
is presented as 2-∆CT. * p < 0.01 as compared to tenocytes cultured in GM. Significance was 
determined by one-way ANOVA and Tukey’s post-hoc test. (± S.D. triplicates). 
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Supplementary Fig. 5: Macroscopic images 
of collagen gel constructs anchored in 
silicon molds at 2, 3, 4 and 5 days after TC-
microtissue seeding of GM or TDM-II 
treated cultures. Scale bar = 1 cm. 
Supplementary Fig. 6: Representative 
images of collagen gel-embedded GM- and 
TDM-II-treated TC-microtissues in situ at 
12 and 24 h after seeding. Scale bar = 100 
μm. 
Supplementary Fig. 4: Western blot analysis of protein 
lysates (40 g) from equine TC-microtissues treated 
with GM (GM) or TDM-II (TDM-II). Protein (10 g) from 
native equine tendon (NT) was used as positive control. 
Protein samples were loaded onto an SDS-PAGE gel 
and tenomodulin detected using a specific antibody 
targeting the N-terminus of human tenomodulin. A 
monoclonal tubulin antibody was used as a loading 
control. 
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Supplementary Fig. 7: Visualization of tenocyte and collagen fibre alignment in hematoxylin and eosin 
stained paraffin wax sections of 3D collagen constructs 5 days after seeding with TDM-II-treated TC-
microtissues. (A) Scale bar = 50 μm. (B) Scale bar = 20 μm. Arrow, orientation of collagen gels based on 
their positioning in anchored silicon molds. 
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5.2  Additional / unpublished data 
5.2.1 Characterization of equine tenocytes in the MT format 
Gravity assisted assembly of equine adult tenocytes (EATs) and fetal tenocytes (EFTs) leads to the 
formation of MTs. Size of MTs was dependent on cell number per tissue and incubation time, where 
a decrease in MT size was observed over time (Fig. 5, 6). Culture periods of 6 days were feasible with 
25 μl of medium per well in the Terasaki plates for hanging drop cultures.  
 
 
 
 
  
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incomplete assembly of the cells was observed at 2 days in hanging drop culture as identified by the 
irregular shape of MTs in hematoxylin and eosin (H&E) stained paraffin wax sections (Fig. 7A and 8A).  
After 4 days in hanging drops, the cells had fully assembled to form round MTs (Fig. 7B and 8B). By 
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Fig. 5: Formation of MTs with different numbers of EATCs/MT  
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Fig. 6: Decrease in size over time in MTs from EFTs 
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day 6, elongated cells were visible in the MTs (Fig. 7C). However, in MTs assembled from EFTs, small 
dark stained cell fragments were visible at 4 days (Fig. 8C). Cell fragmentation and the resulting 
empty spaces within the MTs composed of EFTCs was even more obvious at day 6. Active caspase 
immunostaining revealed increasing rates of apoptosis over time in MTs composed of EFTs (Fig. 8D) 
as compared to EATs MTs (Fig. 7D). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To analyze gene expression, RT-PCR and RT-qPCR was carried out. For RT-PCR, primers were designed 
for COL1A2, TNC, SCX, TNMD and the ribosomal subunit 18s, which served as the housekeeping gene 
control (Fig. 9). In native tendon all selected genes were expressed (Fig. 10). In contrast to this TNMD 
was not expressed in monolayer culture or in MTs composed of EATCs (Fig. 11) and EFTCs (Fig. 12). 
Fig. 7: MTs composed from EATs at 2 (A), 4 (B) and 6 (C) days 
stained with H&E and at 6 days (D) with active caspase 
immunostaining  
A B C 
D 
Fig. 8: MTs composed from EFTs at 2 (A), 4 (B) and 6 (C) days 
stained with H&E and at 6 days (D) with active caspase 
immunostaining  
A B C 
D 
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Target 
Gene 
Product 
size 
Annealing 
temp. 
Sequence 
COL1A2 152 bp 55° C F: 5’ GAGCAGCGGTTACTACTGGATT 3’ 
R: 5’  TCTTGGCCTTGGAACTTCTG 3’ 
TNC 177 bp 55° C F: 5’ TGGCCACTTACTTACCTGCAC 3’ 
R: 5’ TGGTCTCTGGCCTCCTTAGA 3’ 
SCX 200 bp 55° C F: 5’ CTGGCCTCCAGCTACATCTC 3‘ 
R: 5‘ CTGAGGCAGAAGGTGCAGAT 3’ 
TNMD 203 bp 55° C F: 5‘ GATCTTCACTTCCCTACCAACG 3‘ 
R: 5‘ CCTCGACGGCAGTAAATACAA 3‘ 
18S 219 bp 55° C F: 5’ CGCGGTTCTATTTTGTTGGT 3’   
R: 5’ AGTCGGCATCGTTTATGGTC 3’ 
Fig. 9: primer sequence of target genes for RT-PCR 
Fig. 10: RT-PCR from native adult and fetal tendon 
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Fig. 11: RT-PCR from EATs in monolayer culture and in MTs 
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TaqMan gene expression assays for equine COL1A2, SCX, TNMD, COL2A1, SOX9 and GAPDH were 
commercially available and therefore used for RT-qPCR. In native tissue samples expression levels of 
COL1A2 and TNMD were significantly higher in fetal tendon compared to adult tendon, whereas SCX 
expression was higher in adult tendon tissue (Fig. 13). 
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Fig. 12: RT-PCR from EFTs in monolayer culture and in MTs 
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Fig. 13: Relative expression levels of 
COL1A2, SCX and TNMD in native adult 
and fetal tendon 
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In monolayer culture, COL1A2 expression levels were comparable between EATs and EFTs, although 
SCX expression levels were lower in EFTs (Fig. 14). COL1A2 expression levels were lower in the MT 
format as compared to monolayer culture, and decreased over time. SCX expression levels were 
comparable between EAT-MTs and monolayer cultures (Fig. 14). In MT-EFTs cultures, expression 
levels for COL1A2 and SCX were already much lower after 2 days and rapidly decreased over time, 
corresponding to the increased rate of apoptosis seen in histology sections. TNMD expression was 
not detectable in any of the culture formats at any time point (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To evaluate a possible protective effect of dexamethasone on tenocyte viability in 3-D culture, 
different concentrations of dexamethasone were added to the medium in the hanging drop system. 
A concentration dependent effect on time for MT formation could be seen in EFTs (Fig. 15). 
Unfortunately, gene expression levels of COL1A2 and SCX were further decreased (Fig. 16). Because 
of this EFTs were considered as being an unsuitable cell source for the MT format. 
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Fig. 14: Relastive expression levels of COL1A2 and SCX in monolayer culture and MTs 
from EATs and EFTs 
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Fig. 15: Dexamethasone concentration dependent accelerated formation of MTs from EFTs; (A) 
0μM, (B) 1 μM, (C) 10 μM, (D) 100 μM, (E) 1000 μM Dexamethasone, observation period 2 days   
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Fig. 16: Relative expression levels of COL1A2 and SCX in MTs composed of EFTs under the influence 
of different concentrations of dexamethasone. 
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5.2.2 Co-culture of EATs and EFTs with MSCs 
Equine MSCs were harvested from bone marrow or adipose tissue and cultured in the MT format 
alone (Fig. 17), or in combination with EATs or EFTs (Fig. 18). Irrespective of cell ratio, assembly of 
MTs was comparable to hanging drops consisting of EATs or EFTs alone. Interestingly, the expected 
apoptotic appearance of EFTs in MTs was not observed when co-cultured with MSCs, suggesting a 
possible protective effect of MSCs on EFTs survival. However, further evaluation is needed to confirm 
this. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
  
 
 
 
 
Osteogenic differentiation capacity of MSCs was evaluated in the MT format. Interestingly osteogenic 
differentiation, demonstrated by positive Alizarin Red S staining was accelerated in the MT format as 
compared to monolayer culture (Fig. 19) and was faster in BMSCs compared to ASCs (data not 
shown). RT-qPCR analysis was performed for COL1A2, COL2A1, COL3A1, SCX, TNMD, TNC, SOX9, 
TIMP1, MMP1, MMP3, MMP13, IGF1 and IL1 using custom designed primers. Relative gene 
expression levels are shown in Fig. 20 and 21. COL2A1, TNMD and IL1 were not detectable in any of 
the cultures (data not shown). 
 
 
ASC 
Fig. 17: H&E stained paraffin wax section of MTs composed of 
equine ASC 
ASC: EAT = 3:1 ASC: EAT = 1:1 ASC: EAT = 1:3 ASC: EAT = 1:9
ASC: EFT = 3:1 ASC: EFT = 1:1 ASC: EFT = 1:3 ASC: EFT = 1:9
Fig. 18: H&E stained paraffin wax sections of MTs composed of co-culture of ASCs and EATs or EFTs 
Results 
 
 
 
 
69 
 
 
 
 
 
 
 
 
 
 
 
 
When calculated as a ratio, co-culture of EATs and ASCs demonstrated a decrease in COL3A1:COL1A2 
(Fig. 22). Evaluating the influence of ASCs on equine tenocytes in the MT format by fold change of 
gene expression levels was somewhat disappointing. Tendon associated genes like SCX and TNC were 
lower in the co-cultures. The slight increase in COL1A2 expression in the co-culture may be explained 
by the fact, that expression of type I collagen is higher in ASCs than in EATs (Fig. 23). 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 19: A: monolayer culture of equine ASCs with normal growth medium (left panel) or 
osteoinduction medium (right panel) at day 14; B-C: ASC-MTs cultured for 6 days without 
osteoinduction (B) or with osteoinduction (C). In all cases, red staining signifies mineral 
deposition; Alizarin Red S staining  
 
A B C 
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Fig. 20: relative gene expression levels of different ratios of co-culture of EATs and ASCs in MTs at 
day 6, GAPDH served as house keeping gene  
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Fig. 21: relative gene expression levels of different ratios of co-culture of EFTs and ASCs in 
MTs at day 6, GAPDH served as house keeping gene  
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Fig. 22: Ratio of COL3A:COL1A relative expression in 3-D co-culture of EATs, ASCs, or EATs + ASCs; 
expression levels were normalized to the housekeeping gene GAPDH and expression values 
expressed as ratios of COL3A:COL1A. 
Fig. 23: Fold change of gene expression levels comparing MTs of EATs or EFTs alone and in 
combination with ASCs at day 6 
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5.2.3  Mechanical stimulation of equine tenocytes 
Mechanical stimulation was initially performed using a custom made bioreactor, which had 
previously been used to generate tissue-engineered blood vessels from human artery-derived 
fibroblasts and endothelial cells (346). The bioreactor setup contained a control unit, a pulsatile 
pump, a medium reservoir and the assembly device within a falcon tube (Fig. 24). The assembly 
device was modified in a way that MTs could be assembled in a newly designed agarose mold around 
the silicon tube (Fig. 25). To reduce the risk of infection and possible loss of pressure, tubing was 
replaced by less elastic plastic tubes using a Luer-Lock system. Furthermore, new media reservoirs 
with a Luer-Lock system were produced. MTs were harvested and transferred into the agarose mold 
and fused to form a ring shaped tissue construct (Fig. 26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24: A: schematic drawing of the custom made bioreactor setup (346); B: image of the modified 
system with a) pulsatile pump, b) medium reservoir and c) assembly device 
Fig. 25: agarose mold to enable 
assembly of MTs around the 
silicon tube 
Fig.: 26: macroscopic view of a ring shaped tendon 
tissue construct from non-stimulated EFTs 
c b a 
A B 
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As histologic evaluation revealed no obvious differences between mechanically stimulated and 
unstimulated constructs (Fig. 27), expansion of the silicon tube and thereby the amount of 
mechanical stimulation was assessed by means of a high resolution slow motion camera and 
revealed only minor expansion rates. Reducing the inner lumen of the silicon tube with a custom 
made reduction device to an inner diameter of 5 mm, led to controllable expansion rates from 0.7 to 
7.2%. Stimulation with 5% expansion of the silicon tube resulted in ring shaped tissue constructs, 
which in contrast to unstimulated constructs displayed a rough and irregular surface (Fig. 28).  Active 
caspase immunostaining revealed lower rates of apoptosis in mechanically stimulated as compared 
to unstimulated constructs (Fig. 29). As further histologic evaluation detected no influence of 
mechanical stimulation on cell orientation (Fig. 29) and gene expression analysis (Fig. 30) was 
somewhat uninformative, this custom made, scaffold free bioreactor was not continued any further. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Fig. 27: H&E stained paraffin wax section of ring shaped tendon tissue construct composed from 
MTs of EFTs cultivated without (A) or with mechanical stimulation (B) for 7 days 
A B 
Fig. 28: ring shaped tissue constructs from EATs; (A) was cultivated for 10 days without mechanical 
stimulation, (B) was cultivated unde 5% mechanical stimulation for 10 days 
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Fig. 29: H&E stained paraffin wax section of ring shaped tissue constructs composed of EATs; 
construct (A) has been cultivated without and construct (B) with 5% mechanical stimulation for 
10 days. Inlet shows active caspase 3 immunostaining of the ring shaped tissue constructs 
Fig. 30: relative expression levels of COL1A2, SCX and TNMD in MTs 
composed of EATs over time and in a ring shaped tissue construct after 
10 days of mechanical stimulation; ND: not detectable 
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To further characterize MTs under the influence of mechanical stimulation, a pilot study was carried 
out using the STREX-ST-140™ from B-Bridge International in cooperation with the Institute for 
Biomechanics, Department of Health Sciences and Technology at the ETH Zurich. The STREX-ST-140™ 
allows for custom set different uniaxial strain rates at different frequencies. As commercially 
available chambers allow only for 2-D culture, molds to produce silicon chambers for 3-D culture 
were designed in collaboration with the ETH, Zurich. Single EATs and MTs composed of EATs were 
embedded in a 0.8% collagen scaffold and, after a setting time of 2 days, stimulated with 5% strain at 
1 Hz twice a day for 60 minutes each for a total period of 12 days. In single cells, no differences 
between the stimulated group and the unstimulated controls were detected. Cells exhibited a round 
shape with no orientation to the direction of mechanical stretching. Overall, cell density was low. 
There were no signs for remodeling of the extracellular collagen matrix visible (Fig. 31).  In MTs 
cultivated in the collagen matrix for 12 days without mechanical stimulation, empty spaces, initially 
occupied by MTs, and low numbers of rounded cells in the scaffold were observed (Fig. 32). In 
contrast, in MTs cultivated under mechanical stimulation, elongated fibroblast-like cells orientated 
according to the direction of mechanical stimulation could be identified. Furthermore, cells with a 
tenocyte like phenotype migrating out of the MTs and a first staggered arrangement of cells was 
visible. The collagen matrix appeared less homogeneous as compared to the other groups with fiber 
orientation according to the direction of strain applied (Fig. 32).  With the question in mind, if a 
collagen scaffold is necessary for mechanical stimulation of tendon-derived fibroblasts in vitro or if 
the old bioreactor was unsuitable because of other reasons, a ring shaped tissue construct, 
assembled in the agarose mold, was cut and placed strait in the collagen scaffold. For unknown 
reasons, stimulation in the STREX-ST-140™ had no detectable effect, not at the interface between 
the collagen scaffold and the MTs, nor within the tissue construct itself (Fig. 33).  
 
 
 
 
 
 
 
 
 
 
A B 
Fig. 31: H&E stained paraffin wax section of single EATs 
embedded in a collagen scaffold cultivated without (A) and 
with mechanical stimulation (B) for 12 days  
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Based on the findings of this pilot study the STREX-ST-140™ appeared to be suitable for further 
evaluation of the MTs and was therefore purchased for further experiments. Production of the 
silicon chambers was accompanied by a flat learning curve and was somewhat time consuming, but 
was finally established. As no incubator with a pull-trough working channel was available at the 
Center for Applied Biotechnology and Molecular Medicine (CABMM), the new bioreactor was set up 
at the Center for Clinical Studies at the Tierspital Zürich. Cell cultivation, MT production and loading 
of the silicon chambers with the collagen scaffold, single cells or MTs was performed at the CABMM. 
After collagen gel had polymerized, chambers were transported to the Center for Clinical Studies.   
First experiments with single EATs revealed a cell-concentration dependent shrinkage of the collagen 
scaffold (Fig. 34a), which was not observed in the pilot study conducted at the ETH. Time of onset of 
mechanical stimulation had no influence on the amount of shrinkage (Fig. 34b).  
B A 
Fig. 32: H&E stained paraffin wax section of MTs composed of EATs embedded in a collagen scaffold 
cultivated without (A) and with mechanical stimulation (B) for 12 days 
Fig. 33: H&E stained paraffin wax section of straightened ring shaped tissue construct embedded in 
the collagen scaffold after 12 days of mechanical stimulation 
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Even though a lot of effort was undertaken, it was not possible to attain results with the MTs in the 
new bioreactor, as were obtained in the pilot study at the ETH, Zürich. Irrespective of duration, 
amount, rest period and strain rates of mechanical stimulation or collagen concentration of the 
scaffold, cells within the MTs underwent apoptosis, leaving empty holes in the collagen scaffold as 
seen by histologic evaluation (Fig. 35). 
  
 
 
 
 
 
 
 
To rule out insufficient gas exchange for the cells in the MTs embedded in the collagen scaffold, a 
new larger lid for the bioreactor was constructed, containing filter protected openings. Temperature 
within the bioreactor was determined not to exceed 37 °C with the incorporated cooling system. 
Special attempts were also made to keep the pH of the collagen between 7.2 – 7.4. As experiments 
with MTs embedded in collagen scaffolds in the silicon chambers under static tension revealed 
favorable results when carried out at the laboratory of the CABMM, but not when carried out at the 
Center for Clinical Studies, it was concluded that transportation of the cells in the MTs embedded in 
the collagen scaffold were most likely to blame for the poor outcome.
A 
EAT1b, P5, MT 5.000, 2.5D, 10D Bio 
Fig. 35: H&E stained paraffin wax section of the collagen 
scaffold with empty holes initially filled by MTs after 10 
days of mechanical stimulation 
Fig. 34: (A) cell-concentration dependend shrinkage of the collagen scaffold after 4 days; (B) 
comparable shrinkage of the collagen scaffolds irrespective of onset of mechanical stimulation 
after 2 days 
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6 Overall discussion 
Injuries of the weight bearing flexor tendons are one of the most common forms of musculoskeletal 
injuries that occur in horses (1-3, 5), with a significant impact on athletic performance and animal 
welfare. This is not only true for race horses, but also for horses performing in other sporting 
disciplines as well as pleasure horses (6-11).  Even though different sporting disciplines place 
different loads on the locomotor system, it is mainly the SDFT and the SL, which are the main energy 
storing tendons being most commonly affected (2, 5, 11). Their limited adaptive capacity after 
skeletal maturation (5, 50), their operation close to their functional limits (43) and the accumulation 
of age and exercise related degenerative changes (52) are discussed as major predisposing factors.  
The long convalescence period after injury and the insufficient healing response of the tendon 
leading to the formation of mechanical inferior scar tissue, and subsequent high re-injury rate, have 
stimulated ongoing research to improve tendon healing for the last decades. Unfortunately, none of 
the proposed treatment modalities have so far proven to be superior to conventional treatment 
(131, 132, 134, 135, 138, 143-145, 147, 148, 230). The use of MSCs or growth factors by means of 
PRP currently represent two of the most investigated clinical treatment regimes for tendon injury, 
with marketing being ahead of scientific evidence. 
The significance of tendon injury is not only limited to horses but is also of paramount importance in 
humans (12, 13), where the Achilles and patellar tendon, the rotator cuff and the lateral and medial 
elbow tendon are the most commonly injured structures (14-16). With an increase in the aged 
population and participation in recreational sporting activities, the incidence of tendon injuries in 
humans has risen in the last decades (18, 19), thereby prompting improvements in treatment 
modalities for tendon healing.   
As no single animal model can fully reproduce the naturally occurring situation, several animal 
models may have to be used in a concerted effort to study the different aspects of tendon injury and 
healing. Because of ethical concerns about animal welfare and the necessity to follow the principles 
of the three Rs (replacement, reduction and refinement), many basic research questions may 
possibly be better answered with in vitro experiments. This becomes more likely as new culture 
formats become available, which more closely resemble the in vivo environment, thereby generating 
more reliable data. In vitro culture of tendon-derived fibroblasts allows for the characterization of 
tendon cells and the monitoring of their response to different treatment modalities. Furthermore, it 
may ultimately lead to the development of new cellular-based tools to support tendon repair 
through tissue engineering approaches.   
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Unfortunately, basic tendon research is hampered by the lack of tendon specific markers. For this 
reason, the genetic characterization of tendon tissue is normally supplemented with histological 
analyses, and where feasible, mechanical testing. Tendon-derived fibroblasts in monolayer culture 
typically exhibit a fibroblast-like appearance, making it impossible to differentiate tendon-derived 
cells from other fibroblastic cells. Furthermore, in monolayer culture they display an unstable 
phenotype and tend to dedifferentiate (262, 310-312), which serves to undermine the reliability of 
the generated data. 3-D cell culture formats, different growth factors and mechanical stimuli have 
been shown to have an impact on the state of differentiation of tendon-derived fibroblasts in vitro 
(214, 262, 263, 268-270, 337, 341, 342). Therefore, the present study described herein aimed to 
characterize equine tendon cells under a 3-D culture system, and evaluate the most appropriate 
stimuli with which to maintain functional differentiated tenocytes in vitro.  
Gravity assisted assembly of equine adult tenocytes (EATs) and equine fetal tenocytes (EFTs) using 
the hanging drop system led to the formation of microtissue spheroids (MTs). The size of the MTs 
was dependent on cell concentration and culture duration, with a decrease in size over time. 
Whereas apoptosis of cells was a major finding in MTs composed of EFTs, especially at later time 
points, this was not the case in MTs composed of EATs. Adult tenocytes formed well-organized, 
viable MTs where cells, especially at late stage cultures, appeared to have an elongated, spindle 
shaped tenocyte-like morphology and a basic cell alignment growth pattern. Even though, fetal 
tendon cells were isolated at the end of gestation, the discrepancy in viability of EFTs observed in this 
culture format points to major differences between adult and fetal tenocytes. As undifferentiated 
equine MSCs used in this study, as well as mouse ASCs used in other studies (325, 326), had the 
capacity to form viable MTs, this difference is most likely not just a consequence of insufficient EFTs 
differentiation. Nutrient supply is a limiting factor for prolonged hanging drop culture, as medium 
cannot easily be exchanged in the Terasaki plates. This may necessitate early usage of MTs for 
possible tissue engineering strategies. As EFTs grew well in monolayer culture, but showed increased 
rates of apoptosis in the MT format, an inappropriate nutrient supply possibly due to higher 
demands of EFTs should be considered.  As fetal cells in general have proven great potential for 
regenerative therapies (347-351), further evaluation of EFTs is necessary to determine their possible 
application in tendon regeneration.  
MTs composed of EATs demonstrated an early significant increase in tendon-associated marker 
expression such as COL1A2, COL3A1 and SCX when compared to tenocyte monolayers. 
Unfortunately, they were unable to maintain these elevated levels after prolonged culture times. 
Also Schulze-Tanzil et al. and Stoll et al. noticed a decrease in type I collagen expression levels in 
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high-density cultures of human tenocytes over time (262, 263). In the present study expression levels 
of scleraxis were higher in MTs as compared to monolayer cultures at the different time points. This 
finding is in accordance with Stoll et al. who also found increased expression levels in 3-D high-
density cultures as compared to monolayer cultures (262). In contrast to the study by Schulze-Tanzil 
et al. (263), expression levels of scleraxis did not increase over time in the MT format.  
Interestingly, in the current study, expression levels of the pro-chondrogenic marker SOX9 were 
initially observed as being significantly increased in MTs as compared to monolayer cultures after 2 
days. However, by day 6 SOX9 expression levels had become significantly reduced in MTs as 
compared to monolayers.  It is well known, that tenocytes are able to transdifferentiate to 
fibrochondrocytes under specific culture conditions (352, 353), and that overexpression of SOX9 
converts tenocytes to chondrocytes (354). Furthermore, both SOX9 and COL2A1 have been reported 
as being expressed in native tendon, as well as in tenocytes in vitro (263, 265, 266, 355, 356). 
Importantly, COL2A1 expression was not detectable at any time points in our culture system, and 
histologic evaluation of MTs revealed no evidence of cells with chondrocyte-like morphology.  
The observed increase in SCX and COL21A2 by the tenocytes in the 3-D MT format, suggest that this 
culture system has an immediate beneficial effect on tenocyte differentiation as compared to 
monolayer culture. Unfortunately, this beneficial effect could not be fully maintained over extended 
periods of culture and no detectable levels of tenomodulin (TNMD), another tendon associated 
marker, were present at any time point tested. 
In order to better optimize the tenogenic status of tenocytes cultured under either 2-D or 3-D 
conditions, we next focused our attention on the growth media used in each system. Findings from 
recent studies have strongly hinted at the use of TGF-β and IGF-1, or combinations thereof, to 
enhance and possibly even maintain tenocyte differentiation during extended periods of cultivation. 
Caliari et al. (341) demonstrated that IGF-1 at concentrations ranging from 10 to 200 ng/ml was 
capable of significantly enhancing COL1A2, COL3A1 and DCN gene expression in equine tenocytes 
cultured in collagen scaffolds in the absence of serum for 7 days. By contrast, a study performed by 
Qiu et al. (270) demonstrated that IGF-1 (50 ng/ml) alone was unable to significantly influence COL1, 
SCX or TNMD expression in human tenocytes. However, incubation of cells with TGF-β3 (10 ng/ml), 
or TGF-β3 and IGF-1 together, significantly enhanced gene expression above that of control cultures 
incubated in the presence of serum-supplemented growth medium. In support of this, studies 
investigating the tenogenic potential of primary canine MSCs revealed that combinations of TGF-β1 
and IGF-1 (5 ng/ml of each) were sufficient to induce the expression of COL1, COL3, DCN, SCX and 
TNMD after 7 and 14 days in combination with high density 3-D culture conditions (264). Similarly, a 
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more recent report by Barsby et al. (95) has confirmed a synergistic effect between 3-D growth 
environments and the addition of TGF-β3 (20 ng/ml) in the tenogenic differentiation of equine ESCs. 
Therefore, based on these previous findings, we elected to assess the effects of low-serum media 
containing human TGF-β1 (10 ng/ml) in combination with either human IGF-1 (50 ng/ml) (termed 
TDM-I), or human insulin and L-ascorbic acid 2-phosphate (termed TDM-II) on tenocyte 
differentiation in either 2-D or 3-D culture systems. Treatment of tenocytes in 2-D with TDM-I had a 
moderate effect on most of the genetic markers tested, with the majority of genes being significantly 
increased within the first 2 days of culture as compared to cells cultured in growth medium alone. 
However, induction of TNMD expression was not observed at any time point, and COL1A2 and 
COL3A1 expression levels were reduced by day 6. With regards to 3-D cultures, early significant 
increases in gene expression were limited to SCX only, but at later stages included increases in 
COL1A2, COL3A1, SCX, TNMD and SOX9. In comparison to 2-D cultures, late stage 3-D cultures 
demonstrated modest benefits in terms of COL1A2, COL3A1 and TNMD expression, with similar 
levels of SOX9 being observed. These observations therefore go someway to supporting the concept 
of culturing tenocytes under 3-D conditions in the presence of TGF-β and IGF-1 in order to enhance 
and maintain a tendon like genotype. However, the most pronounced effects were observed in 
culture medium where IGF-1 had been replaced by insulin and L-ascorbic acid 2-phosphate (TDM-II). 
Regardless of which system was used, cultivation in TDM-II resulted in marked increases in the 
expression of all tenogenic gene markers in late stage cultures. 
Furthermore, in comparison to 2-D cultures, 3-D MTs examined at day 6 demonstrated significantly 
enhanced expression levels of COL3A1, SCX and TNMD, with a noticeable decrease in the expression 
of the chondrogenic marker SOX9, and a complete absence of COL2A1. Moreover, not only were the 
expression levels of tenogenic markers maintained in this medium, but were also in some cases 
enhanced at the later stages. Clearly therefore, the combination of TGF-β1, insulin and ascorbic acid 
appears to represent a novel supplement for the purpose of enhancing and maintaining a tendon-like 
genotype in 3-D tenocyte cultures, without inducing chondrocyte- associated gene expression. 
A possible explanation for the increased and more rapid expression of tendon associated markers in 
the 3-D cultures as compared to monolayer cultures, was that the 3-D conditions allowed for a more 
advanced state of tenocyte differentiation, thereby altering their response to the growth media. 
Furthermore, cell surface proteoglycans, which have been shown to act as co-receptors or to 
modulate the response of cells to pericellular matrix molecules and soluble stimuli, have been shown 
to be upregulated in 3-D culture formats. Sawaguchi et al. (268) were able to show a significant 
increase in the expression of syndecan-2, a regulator of TGF-β signaling, in tenocytes cultured under 
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3-D conditions. In addition, they were also able to show that betaglycan, a TGF-β receptor III, 
production and betaglycan gene expression were suppressed in monolayer culture. 
The TGF-βs induce both SCX and SOX9 expression. The divergent pro-fibrogenic or pro-chondrogenic 
influence of this signaling pathway is mediated by a stage-dependent regulation of transcriptional 
signaling repressors that mediate the effects of TGF-β and promote chondrogenesis or fibrogenesis. 
In the study by Lorda-Diez et al. (357), TGF-interacting factor 1 (Tgif1) was identified as a potential 
candidate that may be responsible for the pro-fibrogenic influence of TGF-β. Therefore, the transient 
upregulation of SOX9 observed in the present study may be explained by alterations in TGF-β 
signaling, although further studies are needed to confirm this. 
With regards to IGF-1, it is expressed in uninjured flexor tendons (107) and is upregulated after 
tendon injury and repair (99). In the study by Herchenhan et al., IGF-1 supplementation of 
engineered human tendon tissue imparted a stimulatory effect on fibril diameter and the expression 
of several genes including COL1A, TNMD and SCX in vitro (109). Similarly, we observed a significant 
increase in TNMD expression following IGF treatment, being observed after 6 days of treatment 
under 3-D conditions. However, this effect could be significantly increased following the replacement 
of IGF-1 with insulin, another member of the insulin-like growth factor family, and ascorbic acid.  
Already in 1977, Schwarz et al. (358) demonstrated that ascorbic acid stabilizes the differentiation of 
primary avian tenocytes by helping to restore collagen production in vitro. A literature search 
revealed no results concerning an established positive influence of insulin on gene expression or 
state of differentiation of tenocytes. Interestingly an US patent ((US7985408 B2) covering a tenocyte 
cell culturing method with the supplementation of insulin was found. Mazzocca et al. investigated 
the tenogenic potential of insulin in comparison to IGF-1, bFGF or GDF5 on human BMSCs. They 
found increased gene expression and protein levels of type I and type III collagen, scleraxis, tenascin-
C and decorin in BMSCs stimulated with a single dose of insulin in comparison to untreated controls. 
Expression levels of tendon-associated markers and the corresponding protein levels were 
comparable or even increased in insulin stimulated cells compared to cells treated with IGF-1, bFGF 
or GDF5 (359). 
We could also demonstrate that type I collagen was also increased at the protein level in tenocyte 
MTs cultured in the presence of TDM-II. Furthermore, when assessing protein lysates for the 
presence of TNMD, we detected an additional, high molecular weight protein not observed in MTs 
treated with growth medium alone. It is unclear as to why TNMD was detected in tenocyte cultures 
treated with growth medium at all, as qRT-PCR analysis failed to detect any TNMD mRNA transcript. 
However, a similar finding was also reported by Barsby et al. (95) in which TNMD protein was 
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observed in TGF-β-treated equine ESC cultures in the absence of any detectable levels of TNMD 
mRNA. The cause for such inconsistencies was accredited to disparities between TNMD protein 
turnover and mRNA degradation rates. Therefore, it seems plausible that the 250 kDa band observed 
in the current study represents a high molecular weight variant of TNMD, being present in native 
tendon tissue, as well as being induced in MTs following stimulation with TDM-II. However, the 
relevance of this particular protein species with regards to the normal functioning of tendons 
remains to be determined. In a final series of experiments, we assessed the potential of tenocytes 
within MTs to migrate out from the tissue structures and to re-populate 2-D or 3-D culture 
environments. This was based on the assumption that should such tissue constructs be considered as 
a viable in vivo treatment strategy, then the cells contained within the tissue spheroids would be 
required to grow out and invade the surrounding host tissue in order to mediate their therapeutic 
effects. Indeed, we could demonstrate that tenocytes in MTs treated with TDM-II were capable of 
growing out from the tissues and could proliferate on a 2-D culture surface whilst maintaining a 
tenocyte-like morphology. Moreover, when transferred to collagen gels, MT-derived tenocytes 
treated with TDM-II also had the capacity to promote contraction of the collagen matrix and were 
observed to independently align with respect to the orientation of the collagen structure following 
MT outgrowth. Furthermore, the contraction rate of the collagen was directly dependent on cell 
concentration. Other investigators have also observed similar findings using MSCs (360). Therefore, 
the higher rate of contraction seen in MTs treated with TDM-II is most likely due to increased 
numbers of viable tenocytes within the collagen scaffold, following their migration out of the MTs. 
 
 
6.1 Outlook / Perspectives 
The generation and culture of equine adult tendon cells in hanging drop cultures represents an 
interesting 3-D culture method, which may help to maintain tenocytes in a differentiated state, 
especially when combined with the appropriate growth factor supplementation. In this regard, 
culture medium containing TGF-β1, insulin and ascorbic acid appears to be superior to medium 
supplemented with TGF-β1 and IGF-1 only. Clearly, further studies are needed to optimize growth 
factor supplementation and to elucidate the underlying mechanisms responsible for these effects. 
Using Terasaki plates for the hanging drop culture makes media change unfeasible, thereby limiting 
the time of culture period possible. Culture time could be expanded using fully automated systems 
for hanging drop culture, as provided, for example, by InSphero AG. On the other hand, MTs 
containing differentiated tenocytes can be easily harvested after complete assembly from Terasaki 
plates and could be utilized for tissue engineering approaches.   
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Mechanical stimulation is known to have an impact on gene expression and cell differentiation (69, 
218, 219, 342), being partly mediated through TGF-β signaling (214). Therefore, it would have been 
interesting to characterize equine tenocytes in the MT format, with and without the addition of 
different growth factors under the influence of mechanical stimulation. Furthermore, mechanical 
stimulation has been shown to be necessary for embryonic tendon development and therefore may 
have prevented apoptosis in MTs composed of EFTs. As fetal cells in general have proven great 
potential for regenerative therapies (347-351), further evaluation of EFTs is necessary to determine 
their possible application in tendon regeneration.  
Unfortunately, it was not possible to modify the first custom made bioreactor in a way to allow for 
the cultivation of tenocytes under appropriate mechanical stimulation. Although time consuming and 
quite frustrating, we opted for a different system, the STREX-ST-140™ (from B-Bridge International) 
which seemed a feasible option following a successful pilot study performed in cooperation with the 
Institute for Biomechanics (ETH, Zurich). However, despite our best efforts, we were unable to 
reproduce these results and as such, had to compromise and opt for a static 3-D culture. Therefore, 
further optimization studies are required in order to allow for the STREX-ST-140™ to be used to 
evaluate the effects of mechanical stimulation on the ability of MT tenocytes to repopulate collagen 
scaffolds and to generate tendon tissue. 
In addition to equine tenocytes, we also observed a positive influence of the hanging drop culture 
system on the differentiation capacity of equine MSCs. The osteogenic and adipogenic differentiation 
of equine MSCs appeared to proceed faster in this 3-D culture format as compared to monolayer 
culture. Therefore the MT format with the addition of different growth factors could be adapted to 
investigate possible tenogenic differentiation of MSCs. Furthermore, with an established bioreactor 
system, the influence of mechanical stimulation on stem cell differentiation could also be elucidated. 
Co-cultures with different ratios of EATs and EFTs were also feasible. Although one proposed mode 
of action by which MSCs could enhance tendon healing is through the release of different stimulatory 
factors, we were unable to observe any positive influence of tenocyte/MSC co-cultures on the 
expression levels of tendon associated markers. Further and more refined experiments are needed to 
explore this question. 
In conclusion our findings demonstrate the beneficial effect of culturing EATs as 3-D gravity enforced 
MTs and supports the use of low-serum containing growth medium in combination with TGF-β1, 
insulin and ascorbic acid as an effective means by which to maintain the tenogenic differentiation 
status. Such a system would not only offer potential benefits for tendon tissue formation in vivo, but 
also just as importantly allow for tendon cell and tissue biology to be studied in vitro using conditions 
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that more closely simulate the in vivo situation. This would undoubtedly have a significant impact on 
in vivo experimentation, reducing the number of animals required and thus upholding the philosophy 
of the 3Rs. Furthermore, the hanging drop culture offers a valid system to explore the interaction 
between tenocytes and MSCs and may therefore help to elucidate a possible mode of action by 
which MSCs act to promote tendon healing. Finally, the influence of mechanical cues on the 
tenogenic differentiation of tenocyte MTs needs to be further explored.
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